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Abstract 
The clinical progression of atherosclerotic diseases is influenced by environmental and 
lifestyle factors, and strongly determined by individual genetic predispositions. 
Osteoprotegerin (OPG) has been reported to be involved in the development of 
atherosclerotic disease phenotypes, but less is known about its promoter architecture and 
transcriptional regulation.  
Within this study, 1008 bp of the OPG 5’-flanking region were identified to be sufficiently 
active in osteosarcoma cell line SaOs-2 and U2OS. This portion was therefore further 
analyzed for cell type-specific transcription start sites (TSS). One novel TSS was identified 
225 bp upstream the ATG codon, and position of another TSS was corrected in SaOs-2 and 
U2Os. Sequencing of 1008 bp of the OPG promoter portion in 57 patients with 
cardiovascular disease (CVD) led to the identification of five variants (T-960C, A-946G, 
G-900A, T-864G, and T-159C). Individual subcloning revealed the existence of three 
common molecular haplotypes (MolHaps): [T-960-A-946-G-900-T-864; wild type (wt)], [T-960-G-946-
G-900-T-864; MolHap2], [C-960-G-946-A-900-G-864; MolHap4], which were analyzed by transient 
transfection in SaOs-2 and U2Os. The OPG full length construct (1008 bp) displayed a 
moderate transcriptional activity, whereas activities of MolHaps 2 and 4 were significantly 
reduced (p = 0.0018). Introduction of the -159C allele reduced transcriptional activities of the 
respective full length constructs (p = 0.0014). To identify cis-regulatory regions, serial 
deletion constructs were generated. Truncation of 84 bp (-1020/-936) resulted in a complete 
abrogation of transcriptional activity in both cell lines, indicating a cis-regulatory region within 
being essential for transcriptional activity of the OPG gene promoter. Introduction of the 
-159C allele significantly increased activities of the deletion constructs in both cell lines 
(p = 0.0005). EMSAs and co-transfections revealed specific DNA:protein interactions for the 
MolHaps with Sp1, NF-1/A1.1, and NF-1/B2. EMSA competition assays and ChIP 
experiments identified Egr1 interacting exclusively with the -159T allele. Results propose 
new structural features, the existence of genetically differential functional portions within the 
OPG promoter region, and a transcriptional module composing of Sp1, NF-1, and Egr1 is 
suggested to be involved in OPG gene regulation. 
 
  Introduction 
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1. Introduction 
1.1. Cardiovascular Disease (CVD) 
Globally, cardiovascular disease is the leading cause of death for men and women. An 
estimated 17.5 million people died from cardiovascular disease in 2005, representing 30% of 
all global human deaths. Of these, 7.6 million were due to heart attacks and 5.7 million to 
stroke. If current trends continue, by 2015 an estimated 20 million people will die from CVD 
annually [WHO]. CVD include coronary heart disease (CHD), cerebrovascular disease, 
hypertension, peripheral artery disease, rheumatic heart disease, congenital heart disease, 
and heart failure. 
 
1.1.1. Arteriosclerosis 
Arteriosclerosis (the pathophysiological basis of CVD) is a systemic proliferative and 
inflammatory disease of the arterial wall, with particularly noticeable manifestations in the 
medium and large arteries. It represents a multifactorial disease and is influenced by a 
variety of genetic, as well as environmental factors, such as hypertension, smoking, diabetes 
mellitus, vascular injury, etc. Predominantly, it is a clinically silent process, whose acute 
clinical outcome may be caused by rupture of a single plaque. Artherosclerotic 
plaques/ lesions (atheromata) are asymmetric thickenings of the innermost layer of the 
artery, the intima. The earliest lesion in atherogenesis is the fatty streak, an accumulation of 
lipid-laden macrophages (foam cells). These lesions progress into complex lesions, 
containing an accumulation of lipids and necrotic cells (Figure 1). Arteriosclerosis describes 
any hardening or loss of elasticity of medium or larger arteries, while atherosclerosis 
describes hardening of arteries specifically due to an atheromatous plaque. Therefore, 
atherosclerosis constitutes a form of arteriosclerosis. 
 
1.1.2. Pathophysiology of Atherosclerosis 
Infiltration and retention of low density lipoprotein (LDL), and its modification through 
oxidation (ox-LDL) or enzymatic attack in the arterial intima initiates an inflammatory 
response in the artery wall, causing an increased expression of leukocyte adhesion 
molecules [Skålen et al, 2002; Dai et al, 2004]. The monocyte is the first blood cell to arrive 
at the scene of endothelial activation [Massberg et al, 2002]. Once attached, chemokines 
(e.g. macrophage colony-stimulation factor) produced in the underlying intima, stimulate 
them to migrate through the endothelial junctions into the subendothelial space. Entering the 
arterial wall and up-take of ox-LDL induces monocytes to differentiate into macrophages. 
  Introduction 
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Figure 1 Progression of atherosclerosis over time. (1) Lipoprotein particles, and especially low-
density lipoprotein (LDL), enter the arterial wall and undergo modification, including oxidation. (2) 
These oxidized lipoproteins can incite a cascade of cellular responses that include production of 
inflammatory mediators such as cytokines. (3) One integral early step in the atherosclerotic process is 
the expression of adhesion molecules on endothelial cells. (4) Through adhesion molecules, 
leukocytes attach and ultimately enter the arterial wall, attracted to these sites by chemoattractant 
cytokines, known as chemokines. (5) Monocytes in the vessel wall take up oxidized lipoproteins, 
inducing their differentiation into lipid-laden foam cells. (6 and 7) Vascular smooth muscle cells 
(VSMCs) in the wall respond to many of these as well as other stimuli, with some VSMCs migrating 
out of the media and into the intima. In the intima and the media, VSMCs also proliferate and 
elaborate extracellular matrix that contributes to the formation of the early atherosclerotic lesions as 
well as the fibrous cap seen in later stages of atherosclerosis. (8) Later stages of atherosclerosis 
involve more complicated plaques [Plutzky, 2003]. 
 
This step is critical for the development of atherosclerosis [Smith et al, 1995], and is 
associated with up-regulation of pattern-recognition receptors, including scavenger 
receptors. These receptors facilitate the internalization of a broad range of molecules and 
particles presenting pathogen-like molecular patterns, including ox-LDL [Peiser et al, 2002]. 
Internalized ox-LDL cannot be mobilized from the cell to a sufficient extend and accumulates 
in cytosolic droplets. Thus, by harvesting ox-LDL the macrophage transforms into a 
lipid-laden foam cell, the prototypical cell in atherosclerosis. Immune cells, including T-cells, 
monocytes and macrophages, patrol various tissues in search of target antigens. A T-cell 
infiltration is always present in atherosclerotic lesions. Infiltrating T-cells, predominantly 
CD4+ T-cells, recognize antigens presented as fragments bound to 
major-histocompatibility-complex (MHC) class II molecules. In human lesions, CD4+ T-cells 
reactive to ox-LDL were found [Stemme et al, 1995]. Binding of the T-cell antigen receptor to 
  Introduction 
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an antigen, elicited an activation cascade that results in expression of various cytokines, 
promoting a Th1 response [Frostegård et al, 1999]. Activated T-cells differentiate into Th1 
effector cells and produce the macrophage-activating cytokine interferon-γ (INF-γ), which in 
turn increases the efficiency of antigen presentation and increases expression of tumor 
necrosis factor-α (TNFα) and interleukin-1 [Hansson, 2001]. Acting synergistically, these 
cytokines stimulate the production of a series of pro-inflammatory and cytotoxic molecules in 
macrophages and vascular cells [Szabo et al, 2003]. The process results in proliferation and 
migration of smooth muscle cells (SMC), which elaborate connective tissue within the 
inflamed intima and produce the advanced lesions of atherosclerosis [Ross, 1995]. In an 
advanced atheroma, foam cells and extracellular lipid droplets form the core region, which is 
surrounded by a cap of SMC and collagen rich matrix [Hansson, 2001]. Within SMC adjacent 
to atheromata intracellular microcalcifications may form, and lead to extracellular calcium 
deposits between the muscular wall and the outer portion of the atheromata (intimal 
calcification). In contrast to intimal calcification, medial calcification occurs in the absence of 
inflammatory cell infiltration and lipid deposition, but both processes are linked to arterial 
stiffness [Mackey et al, 2007]. 
 
1.1.3. Cardiovascular calcification 
The elasticity of the large artery walls plays an important role in hemodynamics. They 
increase their diameter during systole and decrease during diastole. This “Windkessel effect” 
lessens blood pressure during systole and facilitates blood flow during diastole. When the 
elasticity of the large arteries decreases, the systolic pressure, normally diminished by the 
“Windkessel effect”, is increased and may result in hypertension professing endorgan 
damage such as renal insufficiency, stroke, and other atherosclerosis related diseases. 
Stiffening of the arterial walls increases with age and/or by vascular calcification. Most 
individuals >60 years of age display enlarged deposits of calcium in their major arteries 
[Allison et al, 2004], leading to reduced arterial elasticity. Cardiovascular calcification is a 
strong indicator for inflammatory disease, usually atherosclerosis, and its extend is directly 
related to the overall burden of atherosclerosis [Rumberger et al, 1995]. 
For most of the 20th century, vascular calcification has been regarded as a passive, 
unregulated, degenerative process occurring within advanced atherosclerotic plaques. The 
concept of regulated ossification as the mechanism responsible for vascular calcification 
emerged in the past decade. The first evidence for regulation of vascular calcification was 
brought by Tanimura et al, who found structures involved in osteogenesis in human calcified 
aortas [Tanimura et al, 1983]. Giachelli et al examined vascular calcification at the molecular 
level, showing expression of a bone matrix protein in vascular smooth muscle cells (VSMC) 
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[Giachelli et al, 1991]. Primary VSMCs express bone matrix proteins when treated with 
β-glycerophosphate (which serves as a phosphate donor), in the presence of alkaline 
phosphatase in vitro [Shioi et al, 1995]. As VSMC undergo osteogenic differentiation, they 
lose expression of smooth muscle cell markers, indicating a de-differentiation process [Steitz 
et al, 2001]. Approximately 15% of carotid atherosclerotic plaque specimens and calcified 
valve tissues display ossification [Hunt et al, 2002; Mohler et al, 2001]. Calcium phosphate 
(hydroxyapatite, Ca3[-PO4]2-xCa[OH]2), which contains 40% calcium by weight, precipitates in 
diseased coronary arteries by a mechanism similar to that found in active bone formation and 
remodeling. Bone formation is characterized by tightly regulated osteoblast production of an 
extracellular matrix (osteoid) that is the substrate for passive crystallization, leading to 
hydroxyapatite formation. Bone formation actually fixes circulating calcium in its mineral 
form, removing it from the bloodstream. Conversely, resorption actively unfixes it, thereby 
increasing circulating calcium levels. In bone, mineral is resorbed by osteoclasts, which 
derive from the monocytic line of hematopoetic cells. Macrophages exposed to particulate 
calcium mineral have been reported to undergo osteoclastic differentiation [Merkel et al, 
1999]. Thus, atherosclerotic plaques, by being rich in monocytes and macrophages, are an 
abundant source of preosteoclasts. Maturation of preosteoclasts (e.g. peripheral blood 
mononuclear cells) to osteoclasts is mainly directed by two cytokines: monocyte 
colony-stimulating factor (M-CSF) and the ligand for receptor activator of NF-κB (RANKL). 
Many key regulators of bone formation and bone structural proteins are also expressed in 
atherosclerotic plaques, including bone morphogenetic protein-2 (BMP-2) [Bostrom et 
al,1993], osteopontin (OPN) [Giachelli et al, 1993; Ikeda et al, 1993], matrix Gla protein 
(MGP) [Shanahan et al, 1994], and osteoprotegerin (OPG) [Dhore et al, 2001]. 
 
1.2. Osteoprotegerin (OPG) as a candidate for calcification risk 
1.2.1. TNF receptor superfamily (TNFRSF) 
The tumor necrosis factor (TNF) superfamily is a group of cytokines with important functions 
in immunity, inflammation, differentiation, control of cell proliferation, and apoptosis. With 
TNFα as founding member, their biological effects are exerted through members of the TNF 
receptor superfamily (TNFRSF). This superfamily includes both membrane-bound and 
soluble receptors. The mammalian TNFR family members are type I membrane proteins and 
characterized by the presence of cysteine-rich domains (CRD), which are the hallmark of the 
family (Figure 2). CRD pseudo-repeats are characterized by intra-chain disulphids generated 
by highly conserved cysteine residues within the receptor chains [Smith et al, 1994]. In 
general, each receptor contains varying numbers of CRD, from B-cell activating factor 
receptor (BAFFR) with only a partial CRD, to TNFR I and TNFR II with the most common 
  Introduction 
 7
structure of 3 CRD, and up to 6 CRD found in CD30. Upon receptor stimulation, some 
members of the TNFRSF are cleaved from the cell surface (e.g. TNFR II), while others are 
directly expressed as soluble forms lacking the transmembrane domain (e.g. OPG). In 
general, receptor activation by TNF family members causes recruitment of several 
intracellular adaptor proteins, which activate several signaling pathways.  
 
 
 
 
 
 
 
 
 
 
 
Figure 2 The TNF/TNFR superfamily. The TNF related ligands are marked in blue, arrows 
indicate interactions with their receptors. The ectodomains of TNFR superfamily are shown in grey 
with the appropriate number of CRD. Death domains within the cytoplasmatic domain are indicated 
red [Hehlgans and Pfeffer, 2005]. 
 
Based on their intracellular sequences, TNFRSF members can be classified into three major 
groups. The first group, including FAS, TNFR I, TNF-related apoptosis inducing ligand 
receptor 1 (TRAIL-R1), TRAIL-R2, TRAIL-R4, and TNF-like receptor apoptosis mediating 
protein (TRAMP), contains so called death domains in their cytoplasmatic domains (Figure 
2). Activation of these members leads to recruitment of intracellular, death domain containing 
adaptors, such as FAS-associated death domain (FADD) and TNFR-associated death 
domain (TRADD). These proteins activate the caspase cascade which subsequently leads to 
apoptosis. TRADD in turn can also interact with TNFR-associated factor (TRAF)-2 and 
receptor interacting protein (RIP), thus activating the nuclear factor κB (NFκB) and Jun 
N-terminal kinase (JNK) pathways, which protect cells from apoptosis (Figure 3) [Stanger et 
al, 1995; Hsu et al, 1996]. The second group contains TRAF-interacting motifs (TIM) in their 
cytoplasmatic domain, and includes amongst others TNFR II, receptor activator of NFκB 
  Introduction 
 8
(RANK), CD27, CD30, and CD40. Activation of TIM leads to recruitment of TRAF family 
members and activation of signaling cascades like NFκB, JNK, p38, extracellular 
signal-related kinase (ERK), and phosphoinositide 3-kinase (PI3K) [Dempsey et al, 2003]. 
The third group, including TRAIL-R3 and OPG, does not contain signaling motifs and 
competes with the other two receptor groups for binding of their corresponding ligands. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 Signal transduction of TNFR I. After binding of TNF, TNFR I recruits TRADD as a 
platform adaptor and assembles alternative signaling complexes. One involves TRAF2, which links 
ligand induced signaling to activation of NFκB and AP-1. Another signaling complex leads to 
internalization of TNFR I. During endocytosis, FADD and caspase 8 are recruited to form the death 
signaling complex [adapted from Hehlgans and Pfeffer, 2005]. 
 
1.2.2. OPG – gene and protein 
OPG was isolated independently by two laboratories [Simonet et al, 1997; Tsuda et al, 
1997], and synonyms such as osteoclastogenesis inhibitory factor (OCIF) or TNF receptor 
related molecule (TR1) have been coined. According to the American Society for Bone and 
Mineral Research Committee, the term osteoprotegerin (OPG) is now recommended. The 
human OPG represents a single copy gene located on chromosome 8 (8q24). It spans 29 kb 
and consists of 5 exons, 4 introns, and is transcribed into four transcripts (2.4 kb, 3.0 kb, 
4.2 kb, and 6.5 kb). The 2.4 kb transcript represents the major transcript and originates from 
transcriptional initiation from a TATA box ~30 bp upstream the transcription start site. The 
3.0 kb transcript is derived form the alternative use of transcription start sites, while the 
4.2 kb and 6.5 kb transcripts result from alternative splicing events [Morinaga et al, 1998]. 
NFκB AP1
TRADD
RIP
TRAF2
TRADD
RIP
Pro-caspase 8
Apoptosis
Internalization
TNF
TNFR I
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High OPG mRNA levels were detected in lung, liver, heart, kidney, spleen, thymus, ovary, 
colon, thyroid, spinal cord, lymphnode, and bone [Simonet et al, 1997; Yasuda et al, 1998]. 
Expression of OPG mRNA and protein in osteoblastic lineage cells is increased by 
cytokines, including IL-1β and TNF-α, by the osteoblast-differentiating factors 1a, vitamin D3 
and bone morphogenetic protein 2 (BMP2) [Hofbauer et al, 1998], by the antiresorptive 
hormones estrogen [Hofbauer et al, 1999] and TGF-β [Takai et al, 1998; Murikami et al, 
1998]. In contrast, mRNA and protein level are downregulated by glucocorticoids [Vidal et al, 
1998] and prostaglandin E2 (PG-E2) [Brändström et al, 1998]. 
OPG is a member of the TNFRSF and represents a secretory basic glycoprotein, existing 
either in a 60 kDa monomeric form or a 120 kDa disulfide-linked homodimeric form. 
Yamaguchi and colleagues characterized the structural domains of the OPG protein. The 
N-terminal portion of the protein, containing domains 1-4, has structural similarity to the 
extracellular CRD domains of the TNFRSF proteins and mediates inhibition of 
osteoclastogenesis. The C-terminal portion contains domains 5 and 6, which are death 
domain homologous regions (DDH), having a high potential for mediating cytotoxic signals. 
Domain 7 contains a heparin-binding site. A cysteine residue (Cys-400) within this domain 
was found to be responsible for dimer formation [Yamaguchi et al, 1998] (Figure 4). 
 
 
 
 
 
 
Figure 4 Structure-function relationship of the OPG protein. OPG domains and their 
biochemical and functional properties are indicated. N2H indicates amino-terminus; COOH, 
carboxyterminus; SP, signal peptide; DDH, death-domain homologous regions [adapted from 
Schoppet et al, 2002]. 
 
1.2.3. OPG and vascular calcification 
OPG was first identified as a key regulator of osteoclastogenesis. Osteoclast formation 
requires the presence of RANKL and M-CSF. These membrane-bound proteins, expressed 
by osteoblasts/stromal cells, are necessary for osteoclastogenesis, and widely involved in 
the differentiation of monocyte/macrophage derived cells. M-CSF acts through its receptor 
on the osteoclast, a transmembrane tyrosine kinase-receptor, leading to secondary 
1 2 3 64 5 7
H2N
SP
COOH
Domain
SH
Cysteine-rich DDH
Inhibition of 
osteoclastogenesis Cytotoxicity
Heparin binding
Dimerization
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messenger activation of tyrosine kinase Src. RANKL is a member of the TNF superfamily 
and activates NFκB through binding to its receptor RANK. By binding of RANKL to RANK, 
and in the presence of M-CSF, RANKL promotes differentiation of osteoclast precursor cells 
to mature osteoclasts, their activation, survival, and adherence to bone surface [Matsuzaki et 
al, 1998; Burgess et al, 1999]. OPG, expressed by osteoblasts, acts as a soluble decoy 
receptor by binding and neutralizing RANKL, thus suppressing osteoclastogenesis, 
osteoclast activity, and inducing osteoclast apoptosis (Figure 5) [Ross, 2000; Khosla, 2001; 
Schoppet et al, 2002]. Besides its key role in regulation of osteoclastogenesis, OPG has 
been reported to be involved in atherosclerosis and vascular calcification. Several 
observational studies show that OPG serum levels correlate positively with the severity and 
progression of CAD, atherosclerosis, and vascular calcification (Figure 6). Jono et al 
reported increased OPG serum level in patients with clinically significant stenosis of the 
coronary arteries, and a significant association of OPG serum level with the presence of 
CAD [Jono et al, 2002]. 
 
 
 
 
 
 
 
 
Figure 5 Regulation of osteoclastogenesis. Factors from osteoblasts/stromal cells interact with 
receptors on hematopoietic osteoclast precursor cells. An excess of OPG suppresses bone resorption 
[adapted from Medscape General Medicine™]. 
 
In multivariate analyses, Kiechl and colleagues reported a significant association of OPG 
with severity and 10-year progression of carotid atherosclerosis, and that elevated OPG 
serum level were a risk factor for vascular mortality [Kiechl et al, 2004]. Associations of 
elevated OPG serum level with diabetes, cardiovascular mortality [Browner et al, 2001], 
development of diabetic vascular complications [Rasmussen et al, 2006], and progression of 
vascular calcification have also been reported [Nitta et al, 2004]. Actually, Olesen and 
colleagues found a downregulation of OPG secretion during accelerated calcification in vitro, 
while differences in the expression of OPG mRNA were not detectable [Olesen et al, 2007]. 
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However, animal models suggest that OPG may protect against vascular calcification. Bucay 
and colleagues reported that OPG-deficient (OPG-/-) mice developed medial calcification of 
the aorta and renal arteries, while no atherosclerotic plaques were detectable [Bucay et al, 
1998]. In ldlr-/- mice, fed an atherogenic diet, development of atherosclerotic lesions, vascular 
calcification, and increased OPG serum level was detected. Accessorily treatment of these 
mice with recombinant OPG resulted in reduced vascular calcification without affecting 
atherosclerotic lesion number and size [Morony et al, 2007]. 
 
 
 
 
 
 
 
 
 
 
 
Figure 6 Potential role of OPG in vascular calcification. Soluble RANKL (sRANKL) and OPG 
are secreted in the atherosclerotic plaque and in the blood stream mainly by smooth muscle cells 
(SMCs) and endothelial cells (ECs). RANKL promotes differentiation of osteoclast precursors (mainly 
monocytes/macrophages [M] and SMCs) into osteoclasts (OC) leading to vascular bone resorption. 
OPG neutralizes the action of RANKL [adapted from Montecucco et al, 2007]. 
 
Bennett and colleagues examined atherosclerotic lesion areas and aortic calcium content in 
OPG-/-.apoE-/- mice at 20, 40, and 60 weeks of age, and found an increase in lesion areas in 
40 and 60 weeks old mice. Older mice (60 weeks of age) had also an increase in the area of 
calcification of the lesions. OPG+/+.apoE-/- mice served as control, and displayed less 
atherosclerotic plaque progression [Bennett et al, 2006]. Since OPG-deficient mice, which 
have no measurable serum OPG, develop arterial calcification of the media and large 
vessels that is preventable by restoration of the OPG gene, elevated OPG levels are 
associated with increased, rather than decreased, risk of cardiovascular disease in human. 
One possible explanation for this discrepancy is that elevated OPG serum levels are rather a 
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response than a cause of vascular calcification. Another hypothesis assumes that the 
increased OPG serum levels are a result from decreased clearance of OPG [Browner at al, 
2001]. 
Besides the associations found for OPG serum levels, associations of single nucleotide 
polymorphisms (SNPs) within the OPG gene, and CAD have also been reported. Soufi and 
colleagues examined SNPs in the OPG gene in a study population, in whom OPG serum 
levels, established CAD risk factors, and coronary findings had been determined. They found 
a particular SNP, T 950C (Acc# AB008822), in the OPG promoter region, whose minor allele 
(TC or CC) was associated with a significantly increased risk of CAD and increased OPG 
serum levels in Caucasian men [Soufi et al, 2004]. Another group assessed intima-media 
thickness (IMT) of the common coronary arteries in a Swedish cohort of apparently healthy 
individuals (n= 59), and found that 950C homozygosity was allele associated with an 
increased IMT and significantly lower forearm blood flow, as compared with the other 
genotypes (TC or TT) [Brändström et al, 2002]. 
 
1.3. Gene expression control 
In general, a gene consists of exon and intron sequences, as well as promoter regions for 
concerting transcriptional activities. Only about 30% of the human genome consists of gene 
regions, of which approximately 90% are intronic and 10% are exonic regions. In total, only 
2-3% of the human genome encode proteins. One of the major findings of the Human 
Genome Project (HUGO) was that the human genome contains far less protein coding 
genes than expected, and that the molecular basis of its plasticity and diversity resides in the 
availability of multiple alternative promoters in the majority of human genes. Each coding 
gene requires at least one promoter, which regulates its transcriptional performance 
depending on tissue and physiological specificities. A promoter is located within the 
5’-flanking region upstream of the first exon of a transcribed gene sequence. In case of 
alternative promoters, from which transcription is driven from alternative TSS, the promoter 
may also be located intronically. For most of the human genes the exact and comprehensive 
localization of promoter regions remains unknown [Eckhardt et al, 2006]. 
 
1.3.1. Levels of transcriptional control 
The concept of eukaryotic transcription consists of five control levels (Figure 7): (a) release 
of DNA from nucleosomal packaging and susceptibility of cis-active regulatory elements, (b) 
assembly of the basal transcription machinery at specific sites (TATA-box or TATA-less 
promoter elements [e.g. initiator element (Inr), downstream promoter element (DPE)]), (c) 
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binding of regulatory proteins which interact with the basal transcription machinery 
(transcription factors (TF), repressors, balancers), (d) recruitment of co-regulating proteins, 
which interact with both, TF and basal transcription machinery without interacting with the 
DNA itself (“bridging-proteins”, e.g. CBP, p300), and (e) secondary or epigenetic 
activation/inactivation by histone acetylation or methylation respectively, and natural 
transcript knock-down by micro RNA (miRNA) interference [Lin et al, 2008]. Another recently 
described important level of control is the combination of transcription and splicing by a 
complex of up to 147 proteins (“mRNA factory”) and the splicosome [Kornblihtt, 2006]. 
 
 
 
 
 
 
 
 
 
Figure 7 Control levels of eukaryotic transcription. (a) DNA release from the nucleosome. (b) 
TATA-binding protein (TBP) and TBP associated factors (TAFs) form the TFIID complex and, together 
with RNA polymerase II and other general TFs the basal transcription machinery. (c) TFs bind to 
upstream regulatory elements, having either activating or repressive functions. (d) Co-factors serve as 
bridges between bound TFs and the RNA polymerase II machinery. All cells use an elaborate 
transcription apparatus to express genes; TATA-less promoters use alternative versions of TBP (box) 
[adapted from R. Tjian, Howard Hughes Medical Institute homepage]. 
 
1.3.1.1. Basal transcription machinery 
The term “promoter” typically refers to the “core promoter” and its adjacent sequences. The 
core promoter surrounds the TSS and comprises 70-80 bp that contain elements like 
TATA-box or initator elements (Inr). This minimal region is required for assembly of the basal 
transcription machinery and initiation of transcription. The “proximal promoter” describes the 
region extending upstream of the core promoter and comprises cis-active elements, which 
present repressor or enhancer elements, serving as transcription factor binding sites (TFBS). 
Interaction of bound TFs with the basal transcription machinery is mediated by co-activator 
proteins [Heintzman and Ren, 2006]. The basal transcription machinery consists of six 
(a)
(b)
(c)
(d)
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proteins: RNA polymerase II (pol II) and five general transcription factors, known as TFIIB, -
D, -E, -F, and -H. The core promoter recognition complex TFIID consists of the TATA-box 
binding subunit (TBP) and 8-12 TBP associated factors (TAFs). It bends promoter DNA 
around pol II and TFIIB, whose N-terminal domain brings DNA to the polymerase surface. 
TFIIE enters the complex and recruits TFIIH, whose ATPase/helicase subunit introduces 
negative superhelical tension in the DNA. The emerging transient bubble is captured by 
TFIIF. DNA can now descend into the active center of pol II, which is capable of unwinding 
DNA, synthesizing RNA, and rewinding DNA, but it is incapable of recognizing a promoter 
and initiating transcription. TFs bound to cis-active elements interact with bridging-proteins, 
which in turn interact with the basal transcription machinery. The assembly of this complex 
leads to the initiation of transcription [Kornberg, 2007]. However, a TATA-box is only present 
in ca. 12% of mRNA genes in humans [Bajic et al, 2004] and in about 30% of promoters of 
Drosophila [Ohler et al, 2002]. TATA-less promoters commonly contain a combination of Inr, 
downstream promoter elements (DPE), and GC-rich regions, often containing binding sites 
for the activating TF Sp1. True TATA-less promoters have no intrinsic specificity for TFIID 
recruitment, therefore certain activators such as Sp1 are proposed, when bound to a 
GC-box, to recruit the TFIID complex via a tethering factor physically associated with TBP 
[Pugh and Tijan, 1991]. 
 
1.3.2. Mechanisms of transcriptional regulation 
1.3.2.1. Epigenetic regulation of gene expression 
Epigenetics can be defined as functional events in the genome physiology that are not 
encoded by the DNA itself. Post-translational modifications of histone proteins in chromatin 
and methylation of DNA are two of the major epigenetic modifications. In its transcriptional 
inactive state, DNA is coiled round a set of eight histones in the nucleosome and further 
condensed to chromatin. Nucleosomes serve as general transcription repressors, assuring 
the transcriptional inactivity of all packaged genes in eukaryotic cells. They can rapidly be 
removed and reassembled in the activated state, making promoter DNA transiently available 
for interaction with the transcription machinery. At this level, dominant mechanisms of 
transcriptional regulation are DNA methylation and histone acetylation.  
In complex organisms that contain a large number of tissue-specific genes, mechanisms to 
permanently turn off transcription of genes, not required in a particular cell-type, are 
mandatory. In fact, 40% of mammalian genes contain CpG sites in their upstream region, 
and approximately 60-90% of all CpG sites in the genome are methylated, predominantly 
intergenic regions [Bird, 2002]. High levels of methylated CpG dinucleotides correlate with 
transcriptional inactivity and nuclease resistance. Changes in the affinity of histones to 
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methylated DNA, or changes in the composition of chromatin could explain the inaccessibility 
of chromatin containing methylated DNA to nucleases. Chromatin compositional changes 
are suggested by the replacement of normal nucleosomal components by methylated CpG 
dinucleotide binding proteins, which may have repressor domains recruiting other proteins 
that might alter chromatin structure [Wolffe, 1998]. 
Alterations in core histone acetylation status might have a causal role in determining the 
influence of chromatin on transcriptional activity: transcriptional co-activators that direct 
histone acetylation have been identified, while co-repressors have been discovered to direct 
deacetylation. Each core histone has two domains: a histone fold domain involved in 
histone-histone interactions and DNA wrapping, and one N-terminal domain outside of the 
nucleosome, where it can interact with other regulatory proteins. These N-terminal domains 
are lysine rich and targets for acetylation. A dramatic increase in the accessibility of DNA to 
transcription factors depends on acetylation of the N-terminal domains [Wolffe, 1998]. The 
mechanism by which histone acetylation controls gene activity is unclear, but one plausible 
idea is that acetylation disrupts internucleosomal contacts, resulting in a less compact form 
of chromatin being more accessible to the transcriptional machinery [Jenuwein and Allis, 
2001]. 
 
1.3.2.2. Regulatory elements 
The assembly of the basal transcription machinery is all that is required for initiating 
transcription in any gene. However, the transcription levels achieved by the core promoter 
are minimal, and upstream factors and elements are required to modify transcription rates. 
Additional transcriptional regulators are cis-active elements that are usually located within 
the upstream region and described as enhancer (increasing transcriptional activity), silencer 
(decreasing transcriptional activity), or response elements. 
In case of enhancers, their regulatory character is independent of orientation and flexible 
with respect to the distance from the gene to be regulated. Binding of activators to this 
enhancer region recruits transcription factors, which are ubiquitous, tissue-specific, or 
differentiation-dependent. Promoter-enhancer communication over large distances requires 
usage of facilitating mechanisms. As a result of enhancer action, a promoter binding protein 
can be recruited, enhancer-promoter interaction may result in a change of activity of an 
already promoter-bound protein, or interactions with promoter-bound proteins may cause 
recruitment of other factors required for transcription initiation. Several models have been 
proposed explaining promoter-enhancer interactions over large distances (Figure 8): (A) 
Interaction of an enhancer-bound activator with a promoter-bound protein is facilitated by 
looping of the intervening DNA (DNA looping model). (B) In the tracking model, the enhancer 
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is used as a loading platform for a DNA tracking protein. Since the tracking protein is leaving 
the loading site (enhancer), the protein may be loaded again and thus accumulating in the 
vicinity of the promoter. (C) The spread-looping model suggests that binding of an activator 
protein to the enhancer induces binding-polymerization of a protein to the DNA. A series of 
small loops is formed during polymerization and the array of proteins may reach the target 
promoter [Dorsett, 1999]. 
 
 
 
 
 
 
 
 
 
Figure 8 Models for enhancer-promoter interaction over distances. The enhancer- and 
promoter-bound proteins are indicated in white and black circles, respectively. DNA binding sites are 
indicated by rectangles. (A) Looping. (B) Tracking. (C) Spreading/looping. Activator bound to the 
enhancer induces highly cooperative binding of a protein (grey circle) to several, closely spaced 
DNA-binding sites. Spreading is accompanied by DNA looping [adapted from Bondarenko et al, 2003]. 
 
Silencers direct an active transcriptional repression and have been located at various 
positions: upstream the promoter region, intronically, and exon- or 3’-UTR [Ogbourne and 
Antalis, 1998]. Enhancers and silencers act bi-directionally over long distances and control 
spatial and temporal patterns of transcription. Their widespread occurrence and universal 
actions require mechanisms to prevent inappropriate regulator interactions, so that long-term 
control prevails. Insulators represent a novel class of DNA sequences that constrain 
regulatory interactions within eukaryotic genomes and restrict enhancer and silencer 
function. Insulators are operationally defined by two functional properties. After binding of the 
corresponding protein, they firstly protect gene expression from positive and negative 
chromatin effects, caused when transgenes are integrated randomly within a genome. 
Secondly, insulators block enhancer-activated transcription, when located between enhancer 
and corresponding promoter, but not when the insulator is positioned upstream of the 
enhancer [Geyer and Corces, 1992; Scott and Geyer, 1995; Rosemann et al, 1993]. 
looping
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Response elements modulate transcription rates in response to external stimuli, e.g. specific 
hormones (e.g. estrogene response element, ERE) or intracellular second messengers (e.g. 
cAMP response element, CRE). 
 
1.3.2.3. Alternative promoters 
In mammalian genomes, alternative splicing is a key mechanism to enlarge transcript and 
protein diversity. A variety of exon combinations enables tissue- and differentiation specific 
gene splicing control form a single gene locus. The mRNA isoforms are usually transcribed 
by alternative promoters by inclusion of alternative first exons. Alternative leader exons can 
affect gene expression in diverse ways, including temporal expression of a gene, tissue- or 
cell type-specific expression, stability of mRNA, translational efficiency, and the structure of 
the N-terminus of the protein encoded by the gene. Differences in N-termini of proteins can 
lead to alterations in protein levels, functions, and localizations [Ayoubi and Van De Ven, 
1996]. This alternative usage depends probably on cell-type and tissue specificity, as well as 
on differentiation status. It is mainly defined as an alternative usage of alternative sequences 
with alternative TSS. 
The usage of alternative promoters becomes more and more evident, suggesting the 
existence of 3.1 promoters per gene on average [Cheong et al, 2006]. In addition to 
alternative promoter usage and TSS, the assembly of alternative TF modules also differently 
regulates transcription. 
 
1.3.2.4. Modularity of transcription factor assembly 
Early studies led to the identification of multiple eukaryotic RNA polymerases and mapping 
of promoter and enhancer sequences, including the core promoter elements (i.e. TATA, Inr, 
DPE), proximal basal level enhancer elements (i.e. GC box, CCAAT), and distal 
gene-specific, signal-responsive elements, such as hormone responsive elements (HRE). 
Genetic approaches in yeast and Drosophila, and purification of transcription factors from 
mammalian cells revealed the existence of large families of sequence-specific activator 
proteins, i.e. Sp1, activator proteins (AP1), or CCAAT enhancer-binding proteins (C/EBP) as 
well as a host of accessory factors like TATA-binding protein (TBP) and general transcription 
factors (i.e. TFIIA, TFIIB, TFIID, TFIIE, TFIIF, and TFIIH) necessary for a functional RNA 
pol II complex.  
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Figure 9 Fundamental elements of eukaryotic transcriptional control. (A) Identification of RNA 
polymerases (yellow/green), core promoter elements (grey), proximal basal level enhancer elements 
(green), gene-specific, signal-responsive distal enhancer elements (i.e. nuclear factor element [NFE], 
blue; hormone responsive element [HRE], purple). (B) Sequence-specific DNA-binding transcription 
factors were isolated biochemically, including specificity-protein 1 (Sp1, green), activator-proteins 
(AP1, green), CCAAT enhancer-binding proteins (C/EBP, green), steroid receptors (i.e. glucocorticoid 
[GR], purple), tissue-specific TFs (NF-κB, blue), components of the core machinery, including 
TATA-binding protein (TBP, red), and general TFs (purple). (C) Discovery of TBP associated factor 
(TAF) subunits (orange). (D) Identification of co-activators and co-repressors mediating between the 
core machinery and sequence-specific elements [adapted from Lemon and Tjian, 2000]. 
 
As the presence of TBP alone is insufficient for transcriptional activation, discovery of 
TBP-associated factors (TAFs) revealed the requirement of co-activators to mediate 
activator responsiveness. Many co-activators and co-repressors were subsequently found to 
be required for mediating signals between sequence-specific TFs and the core machinery. It 
is now evident that one regulator can partner and function with multiple types of co-activators 
and co-repressors, and vice versa (Figure 9). TF work in complexes that are represented on 
sequence level as sets of TFBS. A physical TFBS can be found every 10-15 bp within the 
genome. A functional TFBS requires a cellular context, which is defined by availability of the 
respective binding protein, and a genomic context. Although the respective TF is available in 
a certain cell type, the biological function may require additional binding sites, forming a 
transcriptional module. A transcriptional module consists of at least two TFBS, in certain 
distance relationship and strand orientation. They are present in promoters and enhancers, 
A B
C D
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and can shift within a promoter. Signals are integrated via the interacting TF. With this 
promiscuity, transcriptional models represent the basic elements of regulatory pathways and 
networks (Figure 10). Most genes are regulated by missing different types of activators and 
repressors in a coordinated way. Since biological systems are dynamic, TFs only transiently 
associate with their cognate binding site and co-regulators [McNally et al, 2000; for review 
Lemon and Tjian, 2000]. Gene transcription and the associated complex-forming events are 
of eminent importance, and should be tightly regulated to ensure appropriate and correct 
mRNA expression. Variations within regulatory sequences, such as single nucleotide 
polymorphisms – SNPs, may alter TFBS and/or the affinity of DNA:protein interactions, 
probably affecting gene transcription and protein content. 
 
 
 
 
 
 
 
 
 
 
 
Figure 10 Transcriptional modules define target genes of pathways. Target genes of NFκB 
(black lines) are regulated by several pathways via different interaction partners (different modules) of 
NFκB: CREB (green lines), C/EBP (blue lines), IRF-1 (yellow lines), NFκB (red lines) [adapted from 
Genomatix]. 
 
1.4. Linkage and association studies 
Common forms of CVD are known to be multifactorial and influenced by several genes. Two 
main types of studies are used to identify the genetic cause of a complex disease: linkage 
studies and gene association studies (Figure 11) [Arnett et al, 2007]. 
Linkage analyses use phenotypic and genetic data from families for identifying genomic 
regions that might contain genes possibly influencing a phenotypic trait. Thereby, analyses 
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are initiated without any a priori assumptions. Families are genotyped for polymorphic 
marker at known locations across the genome. The marker data together with phenotype 
data and pedigree data are entered into biostatistical algorithms calculating a degree of 
similarity, how a marker correlates with phenotypic resemblance among family members. 
Once chromosomal regions have been discovered through linkage analyses, gene maps are 
reviewed near the region of significant linkage, and potential causal genes are positionally 
identified. Linkage analyses have been successful in identifying the genetic basis of rare 
disorders, but are less useful in identifying common genetic variants that generally have 
moderate effects. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11 Schematic representation of linkage analyses and association studies. Linkage 
analyses identify chromosomal regions using family structure, and phenotype data (left panel). 
Association studies are hypothesis driven and result in phenotype-genotype association data using 
case-control-study populations (right panel) [adapted from www.goldenhelix.com]. 
For complex disease, such as CVD, high resolution whole-genome association studies, 
typing hundreds of thousands of variants, provide an excellent power to detect 
genotype-phenotype relations, markedly exceeding the power of linkage analyses. 
Association-studies are based on SNPs and/or haplotypes (a haplotype describes a 
combination of alleles on the same chromosome that are inherited together and are 
statistically related), and are designed to compare allele/haplotype frequencies between 
case and control groups. The statistical difference in frequencies between cases and 
controls provides evidence whether an allele/haplotype is associated with the trait. 
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Candidate genes are mostly selected basing its known biological function, significant findings 
in a linkage-study, or both. 
However, a genetic association is not necessarily genetic causation. A genetic variant 
associated with a trait may be causal, or associated with the causal variant within the same 
or another gene (linkage disequilibrium). Both, genome-wide linkage studies and association 
studies, often fail to disclose a specific functional effect of the detected variant(s). 
Consequently, a reliable molecular profiling of genetic variation and a better knowledge of 
the molecular/functional structure of the locus of interest is mandatory. Functional analyses 
of the candidate genes target protein function, structure, stability, and its expression. 
Dysregulation in protein transcription due to genetic variants within the promoter region 
might affect its appropriate expression in response to physiological necessities with 
pathophysiological consequences. Therefore, functional analyses do not include exclusively 
the coding region of a gene, but also the 5’-flanking region harboring the regulatory elements 
of a gene. 
 
1.5. Aim and design of the study 
Vascular calcification is a strong indicator for inflammatory disease, commonly 
atherosclerosis. OPG was chosen as a candidate gene because of its emerging role in 
atherosclerosis and vascular calcification [Bucay et al, 1998]. Genetic predispositions are 
entailed by the functionality of genetic variants and individual haplotype patterns. One 
genetic variant within the regulatory region of OPG was identified and associated with 
elevated OPG serum levels and an increased risk of CAD [Soufi et al, 2004]. 
 
Genetic variants that possibly affect transcriptional regulation of OPG might have an 
influence on OPG expression balance and its cytokine-activity. Within this study, genetic 
variants within the regulatory region of the OPG gene were to identify and comprehensively 
characterized. For this purpose, a sufficiently active promoter portion needed to be identified 
in two OPG endogenously expressing osteosarcoma cell lines SaOs-2 and U2Os. 
Cis-regulatory elements within the sufficiently active promoter portion should be identified by 
serial 5’-deletion. Further, haplotype constellations within the OPG regulatory region were to 
identify by scanning genomic DNA from patients with essential hypertension and/or MI 
(MolProMD cohort). The impact of the detected variants on DNA:protein interactions should 
be analyzed, since alterations in TFBS may influence the affinity of interaction of a certain TF 
for its cognate DNA binding site. Therefore, modified DNA sequences harboring the variant 
or haplotype of interest were to characterize by allele-specific response in electrophoretic 
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mobility shift assays (EMSA). To identify transcription factors presumably participated in 
DNA:protein interactions, in silico analyses should be performed and predicted factors were 
to confirm by co-transfection analyses and EMSA competition assays. 
In a parallel asset, functional effects of the genetic variants on transcriptional activity of the 
OPG gene were to examine in an appropriate cell system. Variants should be analyzed in 
the context of the sufficiently active promoter region, as well as in the 5’-truncated deletion 
constructs by use of reporter gene assays. Reporter gene assays allow to determine and 
quantify transcriptional activity of a chosen promoter region, which is cloned into a 
promoter-less luciferase reporter gene vector; expression of the luciferase gene is 
exclusively driven by the cloned promoter portion. Transcriptional influences of the detected 
variants were compared to the wild type sequence. A concept of a transcription factor 
module involved in transcriptional regulation of OPG should be proposed. 
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2. Material 
2.1. Chemicals 
 
Acidic acid, 96%   Roth, Karlsruhe 
Acrylamide, 40% (AA)   Merck, Darmstadt 
Agarose   Biozym, Hess. Oldendorf 
Ammonium peroxydisulfate (APS)  Roth, Karlsruhe 
Bacto™ Agar    Becton Dickinson, 
    Heidelberg 
Bacto™ Tryptone   Becton Dickinson, 
   Heidelberg 
Bacto™ Yeast Extract   Becton Dickinson, 
   Heidelberg 
Betaine   Sigma, Steinheim 
Bisacrylamide, 2% (BAA)  Merck, Darmstadt 
„Blocking reagent“   Roche Diagnostics, 
   Mannheim 
Boridic acid   Roth, Karlsruhe 
Bromphenole blue   Sigma, Steinheim 
Caseine   Sigma, Steinheim 
Chloroform   Fluka Riedel-de Haën, 
   Seelze  
Coomassie Brilliant Blue R-250  Roth, Karlsruhe 
Dimethylsulfoxide (DMSO)  Roth, Karlsruhe 
dNTPs (dATP, dCTP, dGTP, dTTP)  Rapidozym, Berlin 
1,4-Dithiothreitol (DTT)    Roth, Karlsruhe 
17β-Estradiol (E2)   Sigma Aldrich, Schnelldorf 
Ethanol   Merck, Darmstadt 
Ethidium bromide   Roth, Karlsruhe 
Ethylenediamine-tetraacetic acid (EDTA) Roth, Karlsruhe 
Ethyleneglycol-tetraacetic acid (EGTA) Roth, Karlsruhe 
Ficoll   Fluka Riedel-de Haën, 
   Seelze 
Formaldehyde, 37%   Roth, Karlsruhe 
Formamide   AppliChem, Darmstadt 
Glycerol, 87%   Roth, Karlsruhe 
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β-Glycerophosphate   Sigma Aldrich, Schnelldorf 
Glycine   Roth, Karlsruhe 
HEPES 
(4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) Roth, Karlsruhe 
Imidazole   Roth, Karlsruhe 
Isoamylalcohol   Merck, Darmstadt 
Isopropylalcohol   Merck, Darmstadt 
L-Glutamine   Roth, Karlsruhe 
Lithium chloride   Merck, Darmstadt 
Magnesium chloride hexahydrate  Roth, Karlsruhe 
Maleic acid   Roth, Karlsruhe 
β-Mercaptoethanol   Serva, Heidelberg 
Methanol   Roth, Karlsruhe 
N’, N’, N’, N’-Tetramethylendiamine (Temed) Roth, Karlsruhe 
Nitric acid   Roth, Karlsruhe 
Nonidet P-40 (IGEPAL-C630)  Sigma Aldrich, Schnelldorf 
Phenylmethylsulphonyl fluoride (PMSF) Roth, Karlsruhe 
Poly(dI•dC)/Poly(dA•dT)  Amersham Biosciences, 
   Piscataway, USA 
Polyethylene glycol 4000 (PEG 4000) Roth, Karlsruhe 
Polyvinylpyrrolidone (PVP-10)  Sigma, Steinheim 
Potassium chloride    Merck, Darmstadt 
Protease Inhibitor cocktail with EDTA (Complete) Roche Diagnostics, 
   Mannheim 
Sodium carbonate   Merck, Darmstadt 
Sodium chloride   Roth, Karlsruhe 
Sodium dodecyl sulfate (SDS)  Roth, Karlsruhe 
Sodium fluoride    Serva, Heidelberg 
Sodium hydroxide   Roth, Karlsruhe 
Sodium molybdate   Roth, Karlsruhe 
Sodium orthovanadate   Sigma Aldrich, Schnelldorf 
Sodium pyrophosphate   Sigma Aldrich, Schnelldorf 
Sodium pyruvate   Sigma, Steinheim 
Spermidine   Fluka Riedel-deHaën, 
   Seelze 
Tumor necrosis factor α (TNFα)  Cell Signaling, Frankfurt 
Tris-(hydroxymethyl)-aminomethane (Tris-base) Roth, Karlsruhe 
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Triton X-100   Roth, Karlsruhe 
Tween-20   Roth, Karlsruhe 
Xylene xyanole    Roth, Karlsruhe 
 
 
2.2. Other solutions and reagents 
2.2.1. Sera and media 
Fetal bovine serum (conditioned)  PAA, Pasching 
Fetal bovine serum, iron supplemented Cell Concepts, Umkirch 
Dulbecco’s modified eagle’s medium (DMEM)  Sigma, Steinheim 
Dulbecco’s phosphate buffered saline (PBS) Sigma, Steinheim 
 
2.2.2. DNA ladder and protein marker 
Precision Plus Protein Dual Color Standard Plus BioRad, Munich 
50 bp DNA ladder   Invitrogen, Karlsruhe 
100 bp DNA ladder   Invitrogen, Karlsruhe 
1 kb DNA ladder   Invitrogen, Karlsruhe 
 
2.2.3. Enzymes and antibiotics 
Trypsine-EDTA (0.05%)  Gibco, Karlsruhe 
Ampicillin   Roth, Karlsruhe 
Penicillin/Streptomycine solution  Sigma Chemie, Steinheim 
Spectinomycine   Sigma, Steinheim 
 
 
2.3. Consumables and kits 
5’/3’ RACE Kit, 2nd Generation  Roche, Mannheim 
BCA Protein Assay Kit   Thermo Fischer, Bonn 
Biotin 3’ End labeling Kit  Thermo Fischer, Bonn 
Chemiluminescent Nucleic Acid Detection Module Thermo Fischer, Bonn 
CL-XPosure™ Film   Thermo Fischer, Bonn 
Effectene   Qiagen, Hilden 
Egr1 EMSA Kit   Panomics, Heidelberg 
First Strand cDNA Synthesis Kit  Fermentas, St. Leon-Rot 
High Pure PCR Product Purification Kit Roche Diagnostics, 
   Mannheim 
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Immobilon-P Transfer Membrane (PVDF) Millipore, Bedford, USA 
LightShift Chemiluminescent EMSA Kit Thermo Fischer, Bonn 
Lipofectamine™ 2000   Invitrogen, Karlsruhe 
Luciferase Assay System  Promega, Mannheim 
Magnetic Protein-G beads  Invitrogen, Karlsruhe 
Passive Lysis Buffer (5x)  Promega, Mannheim 
Platinum® SYBR® Green qPCR  Invitrogen, Karlsruhe 
SuperMix-UDG with ROX 
PureLink™ HiPure Plasmid DNA Purification Kit Invitrogen, Karlsruhe 
QIAamp® DNA Blood Mini Kit   Qiagen, Hilden 
QIAprep® Spin Miniprep Kit  Qiagen, Hilden 
QIAquick® Gel Extraction Kit  Qiagen, Hilden 
QuikChange®Multi Site-directed Mutagenesis Kit Stratagene, Amsterdam, 
   The Netherlands 
TRIzol® Reagent   Invitrogen, Karlsruhe 
Whatman® Paper 3MM Chr.  Biometra, Göttingen 
Pipette tips 0.1 µl-1000 µl  Sarstedt, Nürnbrecht 
Reaction tubes 0.2 ml-2 ml  Eppendorf, Hamburg 
   Biozym, Hess. Oldendorf 
15 ml/50 ml tubes   Greiner, Kremsmünster 
   Nunc, Wiesbaden 
Petri dishes   Sarstedt, Nürnbrecht 
Plastics for cell culture   Greiner, Kremsmünster 
PCR plates, microtiter plates  Abgene, Hamburg 
 
 
2.4. DNA modifying enzymes 
Exonuclease I   Fermentas, St. Leon-Rot 
GoTaq® DNA Polymerase  Promega, Mannheim 
Herculase II DNA Polymerase  Stratagene, Amsterdam, 
   The Netherlands 
High Fidelity PCR Enzyme Mix  Fermentas, St. Leon-Rot 
Restriction endonucleases  Fermentas, St. Leon-Rot 
Shrimp Alkaline Phosphatase  Fermentas, St. Leon-Rot 
T4 DNA Ligase   Fermentas, St. Leon-Rot  
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2.5. Antibodies 
primary 
Antibody  Host Manufacturer 
anti-OPG (ab14049)  mouse Abcam, Cambridge, UK 
anti-MAPK2 (6G11)  mouse Nanotools, Teningen 
anti-Egr1 (#4154)  rabbit Cell Signaling, Frankfurt 
anti-Sp1 (MAB10126)  rabbit Upstate (Milipore), Schwalbach 
anti-NF-1 (sc-5567X)  rabbit Santa Cruz, Heidelberg 
anti-ERα  rabbit Chemicon (Milipore), Schwalbach 
anti-ERβ  rabbit Upstate (Milipore), Schwalbach 
 
secondary 
Antibody  Host Manufacturer 
anti-rabbit IgG (#7074)  goat Cell Signaling, Frankfurt 
anti-mouse IgG (RPN4201) sheep Amersham Biosciences, 
   Piscataway, USA 
 
Secondary antibodies were horseradish peroxidase-conjugated. 
 
 
2.6. Plasmids and vectors 
Cloning vectors 
Vector  Type  Manufacturer 
pCR®II TOPO® cloning vector cloning vector  Invitrogen, Karlsruhe 
pCR®8/GW/TOPO® cloning vector cloning vector  Invitrogen, Karlsruhe 
pGL3basic  reporter gene vector Promega, Mannheim 
ptk81-luc3  reporter gene vector Dr. Tadashi Kimura, Kobe,  
    Japan 
 
Control vectors 
Vector  Type  Manufacturer 
pGL3control  reporter gene vector Promega, Mannheim 
pTA/luc  reporter gene vector Clontech, Saint-Germain- 
    en-Laye, France 
pNFκB-TA/luc  reporter gene vector Clontech, Saint-Germain- 
  for NFkB  en-Laye, France 
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pERE2-tk/luc  reporter gene vector  Dr. Gwendal Lazennec, 
  for estrogen receptor (ER) Montpellier, France 
 
Expression vectors 
Vector  Type  Manufacturer 
pCH0  expression vector Dr. Rich Gronostajski, 
    Buffalo, USA 
pCH-NF1-A1.1  expression vector  Dr. Rich Gronostajski, 
  (NF1-A1.1)  Buffalo, USA 
pCH-NF1-B2  expression vector Dr. Rich Gronostajski, 
  (NF1-B2)  Buffalo, USA 
pCH-NF1-C2  expression vector  Dr. Rich Gronostajski, 
  (NF1-C2)  Buffalo, USA 
pCH-NF1-X2  expression vector Dr. Rich Gronostajski, 
  (NF1-X2)   Buffalo, USA 
pGFP  reporter gene vector Amaxa, Cologne 
pEgr1/EGFP  expression vector Dr. Kerstin Duning, Münster 
  (Egr1) 
pRc/CMV  expression vector Dr. Dimitris Kardassis, 
    Heraklion, Greece 
pSp1/CMV  expression vector  Dr. Dimitris Kardassis, 
  (Sp1)  Heraklion, Greece 
 
All following vectors were generated within the course of this study (see 3.1.9, and Figure 
23). 
 
OPG promoter portion constructs 
 
pOPG-159T/luc reporter gene construct,  
 275 bp of OPG 5’-flanking region, 
 according to Acc#.: AB008822 
 
pOPG-159C/luc reporter gene construct,  
 275 bp of OPG 5’-flanking region, 
 bearing variant -159C, 
 according to Acc#.: AB008822 
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pOPG-wt/luc reporter gene construct, 
 249 bp of OPG 5’-flanking region, 
 according to Acc#.: AB008822 
  
pOPG-MolHap2/luc reporter gene construct, 
 249 bp of OPG 5’-flanking region, 
 bearing variant -946G, 
 according to Acc#.: AB008822 
 
pOPG-MolHap4/luc reporter gene construct, 
 249 bp of OPG 5’-flanking region, 
 bearing variants -960C, -946G, -900A, -961G, 
 according to Acc#.: AB008822 
 
OPG deletion constructs 
 
pOPG-Del1/luc   reporter gene construct, 
  1008 bp of OPG 5’-flanking region, 
  according to Acc#.: AB008822 
 
pOPG-Del1-159C/luc   reporter gene construct, 
  1008 bp of OPG 5’-flanking region, 
  bearing variant -159C, 
  according to Acc#.: AB008822 
 
pOPG-D1H2/luc  reporter gene construct, 
  1008 bp of OPG 5’-flanking region, 
  bearing variant -946G, 
  according to Acc#.: AB008822 
 
pOPG-D1H2-159C/luc  reporter gene construct, 
  1008 bp of OPG 5’-flanking region, 
  bearing variants -946G, -159C, 
  according to Acc#.: AB008822 
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pOPG-D1H4/luc  reporter gene construct, 
  1008 bp of OPG 5’-flanking region, 
  bearing variants -960C, -946G, -900A, -864G, 
  according to Acc#.: AB008822 
 
pOPG-D1H4-159C/luc  reporter gene construct, 
  1008 bp of OPG 5’-flanking region, 
  bearing variants -960C, -946G, -900A, -864G, -159C, 
  according to Acc#.: AB008822 
 
pOPG-Del2/luc   reporter gene construct, 
  924 bp of OPG 5’-flanking region, 
  according to Acc#.: AB008822 
 
pOPG-Del2-159C/luc   reporter gene construct, 
  924 bp of OPG 5’-flanking region, 
  bearing variant -159C, 
  according to Acc#.: AB008822 
 
pOPG-D2H4/luc   reporter gene construct, 
  924 bp of OPG 5’-flanking region, 
  bearing variants -900A, -864G, 
  according to Acc#.: AB008822 
 
pOPG-D2H4-159C/luc   reporter gene construct, 
  924 bp of OPG 5’-flanking region, 
  bearing variants -900A, -864G, -159C, 
  according to Acc#.: AB008822 
 
pOPG-Del3/luc  reporter gene construct, 
  665 bp of OPG 5’-flanking region, 
  according to Acc#.: AB008822 
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pOPG-Del3-159C/luc  reporter gene construct, 
  665 bp of OPG 5’-flanking region, 
  bearing variant -159C, 
  according to Acc#.: AB008822 
 
pOPG-Del4/luc   reporter gene construct, 
  275 bp of OPG 5’-flanking region, 
  according to Acc#.: AB008822 
 
 
2.7. Bacteria (E.coli) 
Strain Genotype   Reference 
DH5α (K12) F- φ80lacZΔM15 Δ(lacZYA-argF) Invitrogen, Karlsruhe 
 U169 recA1 endA1 hsdR17(rk-, mk+) 
 phoA supE44 thi-1 gyrA96 relA1 λ- 
 
Mach1™ derivatives of E.coli W strains Invitrogen, Karlsruhe 
 ΔrecA1398 endA1 tonA Φ80ΔlacM15  
 ΔlacX74 hsdR(rK- mK+)  
 
2.8. Eucaryotic cells 
Line Origin   Reference 
SaOs-2 Human osteogenic sarcoma  DSMZ no.: ACC 243 
U2Os Human osteosarcoma  ATCC no.: HTB-96 
HEK293T Human embryonic kidney   ATCC no.: CRL-11268 
MCF-7 Human breast adenocarcinoma DSMZ no.: ACC 115 
 
2.9. Hardware and equipment 
Instrument  Type  Manufacturer 
Autoclave  FVS-2  Fedegari, Albuzzano, 
    Italy 
  Systec VX-75  Systec, Wettenberg 
Cell Counter  Casy® Model TT Innovatis, Bielefeld 
CO2-Incubator (eukaryotic cells) MCO-18AIC  Sanyo, Munich 
Developing machine   Optimax  Protec, Oberstenfeld 
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Gel electrophoresis chamber Mini PROTEAN® BioRad, Munich 
(Acrylamid)  NuPage Novex MiniCell Invitrogen, Karlsruhe 
Gel electrophoresis chamber StarPhoresis  Starlab, Ahrensburg 
(Agarose) 
Gel Imaging  AlphaImagerEC Alpha Innotech Corp, 
    San Leandro, USA 
Sterile Hood (bacteria)  BSD4  Gelaire, Sydney, 
    Australia 
Sterile Hood (eukaryotic cells) HS 12  Heraeus, Hanau 
Luminometer  Sirius V12  Berthold Detection 
    Systems, Pforzheim 
Microbiological incubator B 6120  Heraeus, Hanau 
Microscope  Axiovert 40 CFL Zeiss, Jena 
pH-Meter  Calimatic 766  Knick, Dülmen 
Photometer  Nanophotometer Kisker, Steinfurt 
Scales  Sartorius excellence Sartorius, Göttingen 
Sequence detection system 7500  ABIprism Applied Biosystems, Foster 
    City, USA 
Shaker  GFL 3006  GFL, Großburgwedel 
Shaker (bacteria)  Incubator Shaker New Brunswick 
  Series 25   Scientific, Nürtingen 
Tank Blot Chamber  Mini Trans-Blot® Cell BioRad, Munich 
Thermocycler  PTC-225, PTC-240 MJ Research, Miami, 
  DNA Engine Tetrad (2) USA 
Thermomixer  Thermomixer compact Eppendorf, Hamburg 
UV-table  Transilluminator Intas, Göttingen 
Power Supply  PowerPackBasic BioRad, Munich 
Vortexer  VortexGenie2  Bender&Hobein, 
    Zurich, Switzerland 
  BioVortex V1  Kisker, Steinfurt 
Waterbath  GFL 1083  GFL, Großburgwedel 
Centrifuges  Multifuge 3SR  Heraeus, Hanau 
  Centrifuge 5415C Eppendorf, Hamburg 
  Centrifuge 5417R Eppendorf, Hamburg 
  Centrifuge 5810R Eppendorf, Hamburg 
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3. Methods 
3.1. Molecular biological methods 
All standard molecular biological methods were performed as described by Sambrook and 
Russell [Sambrook and Russell, 2001], or according to manufacturers’ application 
guidelines. Modifications are indicated where applicable.  
 
3.1.1. Preparation of genomic DNA 
Genomic DNA was extracted from white blood cells using the QIAamp® DNA Blood Mini Kit 
according to manufacturers’ instructions (Qiagen). Briefly, 200 μL of human whole blood 
(EDTA-treated) were mixed with 20 µL Qiagen Protease (Proteinase K) and 200 μL buffer AL 
(binding buffer) and incubated at 56°C for 10 min. These lysate buffering conditions allow for 
optimal DNA-binding to the silica-gel membrane of the spin columns. After two washing 
steps, DNA was eluted from the spin column with either dH2O or 10% (v/v) buffer AE 
(Qiagen).  
 
3.1.2. Preparation of total RNA 
Crude RNA was extracted using TRIzol® Reagent (Invitrogen) following the manufacturers’ 
instructions. Briefly, confluent cells in a 75 cm2 culture dish were washed twice with 
Dulbecco’s phosphate buffered saline (PBS; w/o Mg2+, Ca2+) and directly lysed by adding 
1 mL of TRIzol® Reagent. After 5 min incubation, addition of 200 μL chloroform, followed by 
centrifugation separated the probes into an aqueous and an organic phase. The aqueous 
phase was transferred into a fresh tube, and RNA was recovered by precipitation with 
isopropyl alcohol in the presence of 2.5 M lithium chloride, and washed with 75% (v/v) 
ethanol. The RNA pellet was dried and resolved in DEPC treated H2O (RNase free). 
 
3.1.3. Preparation of plasmid DNA 
The method describes the purification of plasmid DNA from bacterial cells, following modified 
protocols of the originally described procedure [Birnboim and Doly, 1979]. For the isolation of 
plasmid DNA from E.coli cultures, the PureLink™ HiPure Plasmid DNA Purification Kit 
(Invitrogen) was used. Cells were spun down, resuspended in resuspension buffer 
containing RNase A, and lysed with lysis buffer. Precipitation buffer was added and the 
lysates centrifuged. Probes were routinely cleared from bacterial endotoxins by an additional 
incubation step with Endotoxin Removal Buffer A and washing with Endotoxin Removal 
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Buffer B. Afterwards the cleared lysate was loaded onto a pre-packed anion exchange 
column. Plasmid DNA was eluted with elution buffer, desalted and concentrated by an 
alcohol precipitation step. 
For Maxi- or Mini- preparation, 100 mL or 2 mL of an overnight culture were used and 
plasmids eluted in 200 μL or 50 μL TE-buffer, respectively. 
 
Endotoxin Removal Buffer A  Endotoxin Removal Buffer B 
50 mM MOPS, pH 7.0   100 mM sodium acetate, pH 5.0 
750 mM sodium chloride  750 mM sodium chloride 
10% (w/v) Triton X-100   1% (w/v) Triton X-100 
10% (v/v) isopropyl alcohol 
 
TE-buffer 
10 mM Tris-HCl, pH 8.0 
1 mM EDTA 
 
3.1.4. Photometric measurement of nucleic acid concentration 
Concentration and purity of nucleic acids was measured photometrically using a 
nanophotometer (Implen). An optical density (OD) of 1 at 260 nm represents a concentration 
of 50 μg/mL of DNA or 40 μg/mL of RNA. The particular elution or storage buffers served as 
blank. The E260/E280 ratio reveals the degree of purity, with 1.9 found in pure DNA 
preparations, and >2.0 in RNA solutions. 
 
3.1.5. Standard Polymerase Chain Reaction (PCR) 
The PCR was first introduced in 1986 by Mullis et al and describes an enzymatic 
amplification of DNA fragments in vitro with two specific oligonucleotides (primer) using a 
thermo resistant DNA polymerase (e.g. from Thermus aquaticus (Taq)) [Mullis et al, 1986]. 
All oligonucleotides used in single applications are listed in the appendix. 
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Standard PCR reaction 
1x Taq polymerase buffer 
0.6 U DNA Taq polymerase 
200 μM of each dNTP 
10 μM of each primer 
5 ng of genomic DNA 
nuclease free water to 25 μL 
 
Standard PCR program 
Initial denaturation 95°C, 5 min 
 
Denaturation 95°C, 1 min 
Annealing* x°C, 45 sec  33 cycles 
Elongation 72°C, 90 sec 
 
Terminal elongation 72°C, 10 min 
 
*Annealing temperatures depended on primer sequence and were calculated as [Tm – 3°C]. 
 
Four modifications were applied when necessary: 
- “Hot start PCR”: Thermocycler was pre-heated to 95°C before placing the reaction tubes 
into. 
 
- “Touch down PCR”: To address problematic sequences, annealing temperatures were 
gradually decreased. The annealing temperature was set 5-10°C over the primer annealing 
temperature and reduced by 2°C every second cycle until the correct annealing temperature 
was reached, and applied for the remaining number of cycles. This procedure allows for an 
enrichment of specific PCR products over any non-specific products [Don et al, 1991]. 
 
- “Nested PCR”: Use for very weak amplification signals. Amplicons from the first PCR run 
undergo a second run with a second set of primers located within the first amplified 
fragment. The higher amount of template in the second PCR run should ensure higher 
amplification results and specificity. 
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- “Real time PCR”: This technique is used to amplify and simultaneously quantify the 
targeted DNA sequence. It enables both detection and quantification (as absolute number of 
copies or relative amount when normalized) of a specific sequence in a DNA sample. The 
procedure follows the general principle of polymerase chain reaction; its key feature is that 
the amplified DNA is quantified as it accumulates in the reaction in real time after each 
amplification cycle. Quantification occurs with the use of fluorescent dyes that intercalate 
with double-stranded DNA. 
 
3.1.5.1. Reverse Transcriptase PCR (RT-PCR) 
Generation of cDNA was performed with First Strand cDNA Synthesis Kit (Fermentas). One 
µg total RNA was mixed with oligo(dT) primers and incubated with Moloney Murine 
Leukemia Virus (M-MuLV) reverse transcriptase for one hour at 37°C. The reaction was heat 
inactivated at 70°C for 10 min. To detect endogenous expression of OPG, cDNA was used 
as template for amplification with specific primers (see appendix) in a semi-quantitative hot 
start PCR. Intactness and purity of the cDNA was routinely controlled by diagnostic PCR for 
human Ribosomal Protein 27 (hRP27). 
 
3.1.5.2. Rapid amplification of 5’ cDNA ends (RACE) 
RACE represents an appropriate method for identification and characterization of 5’ ends 
from RNA message. RACE PCR was performed as described previously [Frohman et al, 
1988], using the 5’/3’ RACE kit (Roche). This technique differs from conventional PCR in that 
it requires knowledge of only a small region of sequence within the target RNA. Briefly, RNA 
was extracted from SaOs-2 and U2Os cells and first strand cDNA was generated using an 
OPG specific antisense primer, followed by d(A)tailing of the 3’ end using terminal 
desoxynucleotidyl transferase (TdT). With the use of an homopolymeric d(T)-anchor primer, 
complementary to the 3’ poly(A) tail, and an antisense primer located within the gene, the 
second strand was synthesized and sequenced (for primer sequences see appendix). 
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First strand cDNA synthesis  Synthesis reaction 
4 μL Synthesis buffer    
2 μL dNTP mixture   55°C 60 min 
1 μg total RNA   85°C 5 min 
1 μL cDNA synthesis primer 
1 μL Reverse Transcriptase 
ad ddH2O to 20 µL 
 
Poly(A) tailing   PCR amplification of d(A)-tailed cDNA 
2.5 μL reaction buffer   5 μL d(A)-tailed cDNA 
19 μL purified cDNA sample  1 μL d(T) anchor primer 
2.5 μL dATP (2 mM)   1 μL antisense primer 
incubate 3 min at 95°C,  1 µL dNTP mixture 
add 1 μL TDT (80 U/µL)  0.5 μL Taq polymerase 
incubate for 30 min at 37°C,  appropriate amount of reaction buffer 
heat inactivate for 10 min at 70°C  ad ddH2O to 50 μL 
 
PCR reaction 
Initial denaturation 94°C, 2 min 
 
Denaturation 94°C, 15 sec 
Annealing* x°C, 30 sec  10 cycles 
Elongation 72°C, 40 sec 
 
Denaturation 94°C, 15 sec 
Annealing*  x°C, 30 sec  25 cycles 
Elongation** 72°C, 40 sec 
 
Final Elongation 72°C, 7 min 
 
*Annealing temperatures depended on primer sequence and were calculated as [Tm – 3°C]. 
**Each successive cycle was elongated by additional 20 sec (e.g. for cycle no. 10 is 40 sec, 
for cycle no. 11 is 60 sec, for cycle no. 12 is 80 sec etc.). 
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3.1.6. DNA/RNA modifying reactions 
3.1.6.1. Restriction endonucleases 
For restriction reactions with endonucleases up to 1 μg of DNA and 1 unit of the appropriate 
endonuclease were used. H2O and 10x reaction buffer were added to a total volume of 
20 μL, incubated for 1 hour at 37°C (depending on the optimal temperature of the used 
enzyme), and heat-inactivated at 70°C for 10 min. 
 
3.1.6.2. Dephosphorylation of DNA 
Restriction with one endonuclease results in compatible ends, which are able to religate. 
Dephosphorylation of 5’ ends of linearized plasmid DNA disables religation and was 
performed using Shrimp Alkaline Phosphatase (SAP). One unit of SAP, the appropriate 
amount of 10x reaction buffer, and dH2O were added to the digestion reaction (see 3.1.6.1) 
to a total volume of 25 μL. Reaction mixtures were incubated at 37°C for 30 min and 
heat-inactivated for 10 min at 65°C. Efficiency of dephosphorylation was controlled by 
religation and transformation (see 3.3.1.3). 
 
3.1.6.3. 3’-end labeling of single-stranded oligonucleotides and subsequent annealing 
Single-stranded oligonucleotides (30 bp) for EMSA experiments were synthesized at a 
minimum coupling efficiency of >98.5% and purified twice by high pressure liquid 
chromatography (HPLC) (IBA, Göttingen). These single-stranded probes, as well as 
double-stranded PCR products, were 3’-biotinylated with biotin-16-ddUTP (Roche) using a 
TdT. Per reaction, 5 pmol of each probe were labeled in a reaction mix containing 2 mM 
CoCl2, 500 pmol biotin-16-ddUTP, and 60 U TdT at 37°C for 30 min. Excess biotin molecules 
were removed via phase separation with chloroform. The following centrifugation step (2 min 
at high speed) separated the solution into an organic and aqueous phase, the latter 
containing the labeled probe. PCR products were purified via column-wash using High Pure 
PCR Product Purification Kit (Roche). 
Since double-stranded blunt or recessed 3’ termini are poor substrates for TdT, 
oligonucleotides were labeled prior to annealing. For PCR fragments, Taq polymerase was 
used, which adds a protruding adenosine to the 3’ end. To generate double-stranded 
oligonucleotides, 20 fmol of each primer were mixed in 100 mM NaCl, heated at 95°C for 
5 min, and then slowly cooled down to room temperature (RT) over night. To generate 
double-stranded, but unlabeled oligonucleotides, 2 pmol of each unlabeled primer were used 
for annealing reaction. Annealing was controlled routinely by gel electrophoresis. 
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3.1.7. Agarose gel electrophoresis 
In an electric field, DNA migrates because of its negatively charged phosphate backbone. 
Agarose concentrations of 1% to 3% were applied in 1x TAE buffer, depending on fragment 
sizes. 
 
50x TAE  6x Loading buffer 
2 M Tris base  0.02% (w/v) bromphenole blue 
50 mM EDTA  0.02% (w/v) xylene xyanole 
adjust to pH 8.0  30% (v/v) glycerol 
with acetic acid  20 mM Tris-HCl, pH 7.6 
  2 mM EDTA 
 
For visualizing DNA double-strands, 0.05 μg/mL ethidium bromide (EtBr) was added to the 
gel solution. 
 
3.1.8. Site-directed mutagenesis 
In vitro site-directed mutagenesis is a valuable technique for modifying vector sequences to 
facilitate cloning and expression strategies. Within this work, site directed mutagenesis was 
used for introducing genetic variants into the respective reporter gene vectors 
(QuikChange®Multi Site-directed Mutagenesis Kit, Stratagene). Allelic variants -960C, -900A, 
and -864G were introduced into the deletion constructs pOPG-Del1/luc and pOPG-Del2/luc 
as follows: Mutant strand synthesis was performed by denaturation of input DNA, followed by 
annealing and extension of the mutagenic primers (see appendix), and ligation of nicks. In a 
subsequent step, methylated and hemimethylated DNA was digested with DpnI (1 hrs, 
37°C), and mutated single-strand DNA was transformed into Mach1™ competent cells. 
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Standard Reaction (templates > 5 kb) Standard mutagenesis PCR program 
2.5 μL QuikChange®Multi reaction buffer Initial denaturation 95°C, 5 min 
0.5 μL Quik Solution 
100 ng template DNA   Denaturation 95°C, 1 min 
100 ng of each mutagenic primer  Annealing   55°C, 1 min 
1 μL dNTP mix   Elongation   65°C, 12 min 
1 μL QuikChange® Multi enzyme blend    (1 min per 1 kb) 
   30 cycles 
 
 
3.1.9. Construction of reporter gene plasmids 
Promoter fragments were generated using genomic DNA from a volunteer, bearing the 
respective variants, as template (oligonucleotide sequences see appendix). One fragment 
included the TATA-box of the OPG promoter and a proximal variant (constructs pOPG-
159T/luc, pOPG-159C/luc), the other harboring four distal variants, representing three 
molecular haplotypes (constructs pOPG-wt/luc, pOPG-MolHap2/luc, pOPG-MolHap4/luc). 
For the latter a 249 bp fragment was amplified using sense primers located -1020 bp 
upstream the major TSS (defined in Accession number AB008822), linked to a SacI site, and 
antisense primers located -772 bp upstream the TSS, linked to a NheI site. The TATA-box 
harboring fragment (275 bp) was generated using sense primers at position -287 bp 
upstream the TSS linked to a SacI site, and antisense primers at position -13 bp upstream 
the TSS linked to a BglII site. For deletion constructs the same antisense primer was used, 
sense primers (linked to a SacI site) were positioned at -1020 bp for the pOPG-Del1/luc 
construct (1008 bp), at -936 bp for the pOPG-Del2/luc construct (924 bp), at -677 bp for the 
pOPG-Del3/luc construct (665 bp), and at -287 bp for the pOPG-Del4/luc construct (275 bp). 
For generation of deletion constructs, genomic DNA with the wild type sequence was used. 
Further, three additional deletion constructs were generated, each harboring distinct allelic 
variants: (I) pOPG-D1H2/luc, being congruent with pOPG-Del1/luc, but harboring the -946G 
allele, (II) pOPG-D1H4/luc, being congruent with pOPG-Del1/luc, but harboring alleles 
-960C, -946G, -900A, and -864G, and (III) pOPG-D2H4/luc, being congruent with 
pOPG-Del2/luc, but harboring alleles -900A and -864G. Introduction of the respective SNPs 
was performed via site-directed mutagenesis using vectors pOPG-Del1/luc and 
pOPG-Del2/luc as template DNA (see 3.1.8). Each of the mentioned deletion constructs was 
generated harboring either the -159T or -159C allele. 
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For transient transfection assays the generated PCR fragments were linked to the 
promoter-less luciferase reporter gene vector pGL3basic (Promega). Therefore, purified 
PCR fragments were cloned into the pCR®II TOPO® cloning vector and transformed in 
competent DH5α bacterial cells (see 3.3.1.3). After plasmid preparation and purification, 
TOPO-constructs were double digested with the respective restriction endonucleases (see 
3.1.6.1). Inserts were purified and subcloned in 5’-3’ orientation into the respective sites of 
the luciferase reporter gene vector pGL3basic (Promega) in a 1:3 ratio in favor of the insert. 
For ligation, 1 U of T4 DNA ligase (Fermentas), the appropriate amount of 10x T4 reaction 
buffer and dH2O to a total volume of 20 μL was used. All reporter constructs were directly 
sequenced (see 3.1.11) to ensure sequence accuracy and identity. 
Standard pCR®II TOPO® cloning reaction  
1 μL salt solution (1.2 M NaCl, 0.06 M MgCl2) 
1 μL pCR®II TOPO cloning vector (10 ng/μL) 
4 μL purified insert 
 
To control reporter gene vector religation, a standard ligation mixture was prepared, without 
adding the purified insert, and transformed into bacterial cells DH5α (see 3.3.1.3). 
 
The isolated 249 bp promoter fragments (-1020/-772) were cloned into the reporter gene 
vector ptk81-luc3 (a kind gift of Dr. T. Kimura) using the Gateway® cloning system 
(Invitrogen). The ptk81-luc3 represents a “self-made“ reporter gene vector based on 
pGL3basic (Promega). A 132 bp fragment of the thymidine kinase promoter (-81/+52, 
V00470) was cloned in 5’-3’ direction into pGL3basic. The resulting reporter gene vector 
ptk81-luc3 allows for the assembly of the basic transcription machinery, but lacks enhancer 
performance (Figure 13). 
The Gateway® cloning technique is based on site-specific recombination properties of 
bacteriophage λ [Landy et al, 1989]. These events occur by recombination at specific 
attachment sequences on phage DNA (attP) and bacteria DNA (attB). The recombination 
process begins, when several molecules of the phage-coded integrase and the bacterial 
integration host factor (IHF) bind tightly to attP. The complex then couples with attB in the 
bacterial chromosome, followed by strand exchange and thereby generating flanking 
two-hybrid att sites (attL and attR) (BR reaction). The reaction can be reversed by addition of 
the phage-encoded Xis enzyme (LR reaction). Purified PCR fragments were cloned into the 
entry vector pCR®8/GW/TOPO®, where the fragment is flanked by attL sequences, and 
transformed in competent Mach1™ bacterial cells (see 3.3.1.3). After plasmid preparation, 
the entry clone was mixed in vitro with the destination vector ptk81-luc3 that carries attR 
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sites. Addition of the LR® Clonase enzyme mix (Invitrogen) results in an expression clone 
carrying the 249 bp promoter fragment (Figure 12). 
 
 
 
 
 
Figure 12 Gateway assisted subcloning. Schematic representation of the four Gateway vectors 
and enzymes involved in cloning reactions. The red arrows represent the fragment of interest. 
[adapted from Katzen, 2007]. 
 
Standard pCR®8/GW/TOPO® cloning reaction  LR® clonase reaction 
1 μL salt solution (1.2 M NaCl, 0.06 M MgCl2)  100 ng entry vector  
1 μL pCR®8/GW/TOPO cloning vector (10 ng/μL)  150 ng destination vector 
4 μL purified insert    2 μL LR clonase 
incubation for 5 min at RT,   add 8 μLTE-buffer 
transformation in competent   incubation for 1 hr at 25°C 
Mach1™ bacterial cells    add 1 μL Proteinase K 
    incubation for 10 min at 
    37°C 
 
3.1.10. Purification of DNA fragments 
Purification of DNA fragments for subsequent applications, like ligation or sequencing, was 
performed either by gel extraction, column wash or enzymatic reaction. 
 
Gel extraction was performed using QIAquick® Gel Extraction Kit (Qiagen). After agarose gel 
electrophoresis, the DNA fragments were excised from the gel, mixed with buffer QG and 
heated 10 min at 50°C for dissolving the gel slice. After applying the sample onto the silica 
membrane of the column, the column was washed two times and DNA was eluted in dH2O. 
For purifying PCR products for further enzymatic reactions or sequencing, the High Pure 
PCR Product Purification Kit (Roche) was used. PCR reactions were mixed with binding 
buffer and load onto a column. After two washing steps, the DNA was eluted in dH2O.  
pCR®8/GW/
TOPO ®
pTk81/luc/GW pOPG/tk-luc
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A rapid one-step PCR clean-up for subsequent sequencing reactions was performed with the 
ExoSAP-it protocol. A mixture of exonuclease I and shrimp alkaline phosphatase (SAP) 
(both Fermentas) was used to digest small single-stranded fragments (e.g. primers) and to 
remove dNTP’s. 
 
ExoSAP-it mixture  
20 U exonuclease I 
10 U shrimp alkaline phosphatase (SAP) 
ad dH2O to 100 μL 
 
Purification protocol 
1 μL of ExoSAP-it mix was used for 5 μL PCR products, incubated at 37°C for 30 min, and 
heat-inactivated for 15 min at 80°C. 
 
3.1.11. Sequencing 
Samples were sequenced (both strains) for detection and localization of genetic variants, 
and to ascertain correctness of DNA fragments and plasmid constructs using an automated 
ABI 3730 fluorescence sequencer with big dye terminator chemistry (PE Applied 
Biosystems) (oligonucleotide sequences see appendix). 
 
Standard sequencing reaction 
5-50 ng purified PCR fragment or 120 ng plasmid DNA 
1.6 μM primer 
5x BigDye buffer 
1 μL BigDye 3.1 
ad dH2O to 10 μL 
 
Probes were sequenced using the sequencing service of the University Hospital of Münster. 
 
3.1.12. Electrophoretic Mobility Shift Assay (EMSA) 
An Electrophoretic Mobility Shift Assay (EMSA) is a common technique to investigate 
DNA:protein interactions. This assay offers the possibility to determine whether a nuclear 
protein extract is capable of binding to a given DNA sequence. A mobility shift assay 
involves the electrophoretic separation of the DNA:protein complexes in a native PAGE. The 
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velocity at which molecules and molecule-complexes move through the gel is determined by 
their size and charge. A control lane contains a single band representing the unbound DNA 
probe. Assuming that a protein is capable of binding to the given sequence, the lane in which 
protein is present will contain a “shifted” band, representing a larger, less mobile 
DNA:protein complex. 
EMSAs were performed using the LightShift Chemiluminescent EMSA Kit (Thermo Fisher). 
Per reaction, 5 μg nuclear protein extracts were incubated in binding buffer with 500 ng pre-
sheared poly dI●dC:dA●dT (1:2) as non-specific competitor, 250 mM Betaine, 5 mM MgCl2 
and a 200-fold molar excess of unlabeled oligonucleotide as specific competitor for 15 min at 
RT. After addition of the labeled OPG probe (see 3.1.6.3), reactions were incubated for 
another 45 min on ice, then submitted to a 6% native PAGE (0.5x TBE; 100 V), and blotted 
onto PVDF membranes (see 3.2.6) (0.5x TBE; 100 V; 60 min). Subsequently, DNA probes 
were cross-linked to the membrane by UV-light (312 nm) for 10 min. 
 
4x binding buffer   6% PAGE 
20 mM MgCl2   2 mL AA/BA, 30% 
240 mM KCl   1 mL 5x TBE 
40 mM HEPES/KOH, pH 7.9  83.7 μL APS, 10% 
5 mM spermidine   3.7 μL TEMED 
16% (w/v) Ficoll   ad dH2O to 10 mL 
 
5x TBE 
45 mM Tris base 
45 mM boridic acid 
10 mM EDTA 
 
After blotting, bands were visualized by Chemiluminescent Nucleic Acid Detection Kit 
(Thermo Fischer). First, membranes were blocked in blocking buffer containing 
streptavidin-horseradish peroxidase conjugate. After four washing steps, membranes were 
incubated in substrate equilibration buffer, and subsequently incubated for 5 min in substrate 
working solution, consisting of luminol/enhancer solution and stable peroxidase solution, 
followed by exposure to CL-X Posure Film (Thermo Fischer) for 30 sec to 5 min. 
 
3.1.13. Chromatin Immunoprecipitation Assay (ChIP) 
Chromatin Immunoprecipitation (ChIP) assays are used to evaluate the association of 
proteins with specific DNA regions. The technique involves crosslinking of proteins with 
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DNA, fragmentation and preparation of soluble chromatin followed by immunoprecipitation 
with an antibody recognizing the protein of interest. The segment of the genome associated 
with the protein is then identified by PCR amplification of the DNA in the immunoprecipitates. 
ChIP was performed as described previously [Boyd et al, 1998; Liu et al, 2000]. About 108 
cells were fixed by adding formaldehyde to a final concentration of 1% (v/v) and incubated by 
modest shaking for 30 min at RT. After that cells were washed twice with cold PBS (Sigma). 
The pellet was then resuspended, lysed, and nuclei were isolated and sonicated until the 
chromatin had an average length of 500-1500 bp. After centrifugation the supernatant was 
incubated with 3 μg of antibody against Sp1 (Upstate), NF-1 (St. Cruz), and Egr1 (Cell 
Signalling) over night at 4°C for immunoprecipitation. The next day 10 μL of magnetic 
Protein-G beads (Invitrogen) were added and further incubated at 4°C for 1-3 hrs. After 
extensive washing the antibody/transcription factor/DNA complex was eluted from the beads, 
subsequently formaldehyde crosslinks were reversed and proteins were digested with 
proteinase K at 67°C over night. The DNA was extracted by phenol/chloroform/isoamyl 
alcohol, washed with 75% (v/v) ethanol, resuspended in water, and used for PCR. 
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3.2. Protein biochemical methods 
3.2.1. Extraction of crude proteins 
Crude protein extracts from cells were harvested by scraping the cells in lysis buffer. Nuclei 
and debris were removed by centrifugation at 4°C for 5 min at 12.000xg, pre-heated 4x SDS-
PAGE sample buffer was added immediately to the supernatants and heated to 95°C for 
5 min prior to aliquoting and freezing. 
 
Lysis buffer   4x SDS sample buffer 
20 mM imidazole, pH 6.8  200 mM Tris-HCl, pH 6.8 
100 mM KCl   8% (w/v) SDS 
1 mM MgCl2   0.4% (w/v) bromphenol blue 
10 mM EGTA   40% (v/v) Glycerol 
0.2% (v/v) Triton X-100 
10 mM NaF 
1 mM sodium vanadate 
1 mM sodium molybdate 
10 mM sodium pyrophosphate 
25 mM β-glycerophosphate 
 
3.2.2. Extraction of nuclear proteins 
Nuclear protein extracts were harvested by a modified procedure of the protocol published 
by Schreiber et al [Schreiber et al, 1989]. Briefly, 107 cells were washed twice with cold PBS. 
After scraping and transfer into centrifugation tubes, cells were spun down for 2 min at 
5000xg at 4 ºC. Pellets were resuspended in a “low salt” buffer and allowed to swell on ice 
for 15 min. After addition of detergent NP-40 and another centrifugation step, the 
supernatant containing the cytosolic protein fraction was removed from the pellet. This was 
resuspended in a “high salt” buffer. After 30 min of incubation, the cellular debris was spun 
down, the nuclear protein fraction aliquoted, snap frozen, and kept at –70°C. 
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“low salt” buffer   “high salt” buffer 
10 mM HEPES, pH 7.9   20 mM HEPES, pH 7.9 
10 mM KCl   0.2 mM EDTA 
1 mM DTT   1 mM DTT 
1.5 mM MgCl2   420 mM NaCl 
protease inhibitor cocktail (complete) 1.5 mM MgCl2 
   0.5 mM PMSF 
   25% (v/v) Glycerol 
   protease inhibitor cocktail 
   (complete, w/o EDTA) 
 
3.2.3. Measurement of protein content 
The protein content of nuclear extracts was measured using the BCA™ Protein Assay Kit 
(Thermo Fischer). A series of dilutions with known concentrations was prepared from bovine 
serum albumine (BSA), serving as standard protein. Protein concentrations were detected 
photometrically and calculated with reference to the standard curve. 
 
3.2.4. SDS-Polyacrylamid Gel Electrophoresis (PAGE) 
Intactness of nuclear protein extracts was routinely ascertained by PAGE and Coomassie 
blue staining. Therefore, 5 μg of each probe were mixed with 4x SDS sample buffer and 
loaded onto a 10% SDS gel as described by Rittenhouse and Marcus [Rittenhouse and 
Marcus, 1984]. 
SDS is an anionic detergent which denatures secondary and non-disulfid-linked tertiary 
structures, applying a negative charge to each protein in relation to its mass and thereby 
creating a nearly uniform negative charge along the length of the polypeptide. The distance 
of the migration in the gel can therefore be assumed to be directly proportional to the size of 
the protein. 
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Stacking gel (4%)   Running gel (10%) 
560 μL AA/BA, 30%   2.5 mL AA/BA, 30% 
675 μL 0.5 M Tris-HCl, pH 6.8  1.9 mL 1.5 M Tris-HCl, pH 8.8 
675 μL 0.5 M imidazole, pH 6.8  75 μL SDS, 10% 
75 μL SDS, 10%   5 μL TEMED 
5 μL TEMED   25 μL APS, 10% 
40 μL APS, 10%   ad dH2O to 7.5 mL 
ad dH2O to 4.2 mL 
 
Run at 80 V, approximately for 30 min Run at 130 V, duration depending on 
   protein sizes 
 
1x SDS running buffer 
25 mM Tris base 
192 mM glycine 
1% (w/v) SDS 
 
3.2.5. Coomassie blue staining 
Protein bands were visualized by incubation of the gel in Coomassie blue staining solution, 
followed by two destaining steps of 30 min each. 
 
Coomassie staining solution 
0.25% (w/v) Coomassie™ Brilliant Blue R-250 
45% (v/v) methanol 
10% (v/v) acetic acid 
 
Destaining solution I   Destaining solution II 
45% (v/v) methanol   5% (v/v) methanol 
10% (v/v) acetic acid   5% (v/v) acetic acid 
 
3.2.6. Western Blot (tank blot) 
From each cell extract, 10 μL were subjected to a 10% SDS-PAGE as described before 
[Rittenhouse and Marcus, 1984], and blotted onto a PVDF membrane following the Towbin 
tank blot protocol [Towbin et al, 1979]. Briefly, a PVDF membrane was activated in methanol 
and placed onto the gel, covered with two sheets of whatman-paper on each site. Air 
bubbles were removed carefully. The “sandwich” was put into a gel holder cassette with fiber 
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pads on each site, and placed vertically into the blotting buffer tank. Blots were run for 1 hr at 
100 V at RT, but using cooling units. 
 
1x Blotting buffer 
25 mM Tris base 
192 mM glycine 
10% (v/v) methanol 
 
After blotting, membranes were allowed to dry completely over night and re-activated in 
methanol the next day. Blocking of non-specific binding sites was performed by hybridizing 
the membranes in blocking solution for 30 min at RT. Proteins of interest were detected by 
immunodetection using specific antibodies (see 2.5) at a dilution of 1:1000 for 1 hrs at RT 
with gentle agitation. Secondary antibodies were given at a dilution of 1:10.000. The 
samples’ even-loading was ascertained by immunodetection of Mitogen Activated Protein 
Kinase 2 (MAPK2) (Nanotools). 
 
Blocking solution   Washing solution (1x TBS-T) 
0.5% (w/v) casein   100 mM Tris base 
1% (w/v) PEG-4000   1.5 mM NaCl 
1% (w/v) PVP-10   0.03% (v/v) Tween-20 
0.1% (v/v) Tween-20   adjust to pH 7.4 
in 2x PBS 
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3.3. Cell biological and microbiological methods 
3.3.1. Prokaryotic cells 
3.3.1.1. E.coli 
Bacteria were cultured at 37°C either in liquid medium (lysogeny broth (LB)-medium) or 
plated on agar plates. Antibiotics were added for specific selection of transformed bacteria. 
For long term storage 15% (v/v) glycerol was added to an over night liquid culture and stored 
at –80°C. 
 
LB-Medium   LB-Agar 
10 g Bactotryptone   15 g Bacto agar in 1000 mL LB-Medium 
10 g Sodium chloride 
5 g Yeast extract    Autoclave at 121°C,  
ad dH2O to 1000 mL, pH 7.0  cool down to 56°C, 
   add appropriate antibiotics 
Autoclave at 121°C for 20 min  (e.g. 100 μg/mL ampicilline) 
 
3.3.1.2. Generation of competent cells 
Competent bacterial cells were generated as follows: 200 mL of LB-medium were inoculated 
with E.coli cells and grown to an OD600 0.5-0.6. After 20 min of incubation in an ice bath with 
gentle agitation, cells were harvested at 4000xg for 15 min (4°C), pellets resuspended in 
10 mL MnCl2-transform buffer, and kept on ice for 10 min, followed by another centrifugation 
step (3000xg, 10 min, 4°C). Finally, pellets were resuspended in 7.4 ml MnCl2-transform 
buffer and mixed gently, followed by dropwise addition of 560 μL DMSO. Aliquots of 100 μL 
were snap frozen in liquid nitrogen and kept at –80°C. All equipment was properly chilled 
prior to processing the bacteria. 
 
MnCl2-transform buffer 
10 mM HEPES, pH 6.8 
15 mM CaCl2 
20 mM KCl 
55 mM MnCl2 
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3.3.1.3. Transformation 
An aliquot of competent cells (100 μL) was thawed on ice, mixed with 4-6 μL of ligation 
reaction or 20 ng plasmid DNA, kept on ice for 25 min, heat-shocked at 42°C for 45 sec, and 
briefly cooled on ice for 2 min. Five-hundred μL LB-medium were added and cells gently 
shook for 35 min at 37°C. Thereof, 150 μL were plated onto antibiotic agar plate and 
incubated over night at 37°C.  
 
3.3.2. Eukaryotic cells 
3.3.2.1. Cell culture 
The human osteoblast-like osteosarcoma cell lines SaOs-2 and U2Os, the human embryonic 
kidney cell line HEK293T, and the breast cancer cell line MCF-7 were maintained in 
Dulbecco’s Modified Eagle Medium without phenol red with 10% (v/v) fetal calf serum (PAA), 
100 U/mL penicillin, 100 μg/mL streptomycin, 2 mM/mL L-Glutamine (all GIBCO), and 1 mM 
sodium pyruvate (Sigma). For cultivation of HEK293T iron-supplemented fetal calf serum 
was used (Cell Concepts). In case, cells were stimulated with 10-8M 17β-Estradiol (E2, 
Sigma), and/or 2 ng/mL recombinant tumor necrosis factor-α (TNFα; Calbiochem). When 
reaching confluence, cells were detached from surface by trypsination for 2 min and splitted 
at appropriate ratios for further cultivation. 
 
3.3.2.2. Storage 
For long term storage, cells were washed twice with PBS, trypsinated, and transferred to 
fresh medium. After centrifugation, cells were placed on ice and resuspended in fetal calf 
serum (FCS) containing 10% (v/v) DMSO. Cells were stored at –80°C and transferred to 
liquid nitrogen the next day. 
Thawing cells was performed as quickly as possible, in a waterbath at 37°C. To remove 
DMSO from the freezing medium, cells were washed with PBS and transferred into 
pre-warmed medium after centrifugation. 
 
3.3.2.3. Transient transfection 
The osteoblast-like cell lines SaOs-2 and U2Os were transfected using Effectene 
transfection reagent (Qiagen). Per reaction 50.000 cells/well were plated in 24-well plates 
and transfected the next day. For both, SaOs-2 and U2Os, 0.2 μg DNA and 1.6 μL Enhancer 
solution were diluted in 60 μL buffer EC, and incubated for 5 min at RT. Subsequently, 4 μL 
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Effectene reagent was added, mixed gently, and incubated for 10 min at RT. After addition of 
350 µL medium, cells were transfected with 415 μL transfection reagent for 10 hrs. 
 
 
 
 
 
 
 
 
 
 
 
Figure 13 Schematic presentation of used reporter gene vectors. Construction of reporter gene 
vectors, containing either a strong viral promoter (pGL3control), a minimal promoter (ptk81-luc3), or no 
promoter (pGL3basic) was making it feasible to clone any promoter portion in front of the luciferase 
gene for detecting its transcriptional activity. With kind permission of R. Telgmann. 
Cell lines HEK293T, EA.hy 926, and MCF-7 were transfected using Lipofectamine 2000 
(Invitrogen). Cells were plated at a density of 100.000 cells per well in 24-well plates and 
transfected the next day. In brief, 0.8 μg DNA were diluted in 50 μL serum-free DMEM. Per 
reaction, 2 μL Lipofetamine 2000 were diluted in 50 μL serum-free DMEM and incubated for 
5 min at room temperature. Subsequently, DNA dilution was added dropwise to 
Lipofectamine 2000 dilution, and incubated for 20 min at room temperature. Cells were 
exposed to the transfection reagent for 6 hrs. For both transfection procedures, cells were 
harvested 24 hrs post transfection with 100 μL Passive Lysis buffer (Promega), and 
luciferase activity was determined using a Sirius single-tube luminometer (Berthold detection 
systems). The cell lysate/luciferase substrate ratio was routinely 20 μL/75 μL. 
Transfection of the truncated promoter constructs (deletion constructs) was performed in 
equimolar amounts of reporter vectors using the inert vector p0GH (Nichols Institute) for 
adjustment of DNA content. The pGL3control vector (Figure 13), in which transcription is 
driven by a powerful viral promoter served as positive control, the ptk81-luc3 vector, 
containing a minimal viral promoter but lacking enhancer performance, and the promoter-
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SV40 late
poly(A) signal
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less pGL3basic served as negative controls (Promega). Transfection experiments were 
repeated at least three times, in triplicates for each plasmid. 
 
3.3.2.4. Cotransfection 
In cotransfection experiments, a transient overexpression of a certain protein (e.g. 
transcription factor) is forced upon cells to analyze its possible effects on transcription of the 
cotransfected reporter gene. Therefore, an expression vector carrying the cDNA of distinct 
proteins was cotransfected with the reporter gene vector in a ratio of 3:1. In this study 
expression vectors for family members of the NF-1 family of transcription factors (pCH-A1.1, 
pCH-B2, pCH-X2, and pCH-C2 [a kind gift of Dr. Rich Gronostajski, Buffalo, USA]), Sp1, or 
Egr1 (a kind gift of Dr. Kerstin Duning, Münster, Germany) were used. 
 
3.4. Study populations 
The current investigation was based on the Münster Molecular Functional Profiling for 
Mechanism Detection (MolProMD) study. The Münster MolProMD Study is a prospective 
study of patients with CVD (MI, essential hypertension) and families, aimed at studying 
molecular genetic mechanism of CVD. The study was approved by the ethics committee of 
the Medical Faculty, Westfälische Wilhelms-University of Münster and written informed 
consent was obtained from all study subjects. 
 
3.5. In silico binding analyses of putative TFBS 
To analyze whether a polymorphic site potentially affects TFBS, a sequence flanking either 
side of the genetic variant was submitted to computational comparison using the AliBaba2.1 
net-based and up-to-date TFBS search tool (http://www.gene-
regulation.com/pub/databases.html) and the TRANSFAC7.0 database. Pairsim and minimal 
matrix conditions as well as factor type were adjusted and analyzed by cross checking with a 
different search engine (match; http://www.gene-regulation.com/cgi-
bin/pub/programs/match/bin/match.cgi). AliBaba2.1 is a program for predicting binding sites 
of TFBS in an unknown DNA sequence. Therefore it uses the binding sites collected in 
TRANSFAC database and is currently the most specific tool for predicting TFBS. It pairwise 
aligns the known sites to the unknown sequence, forms small sets of sites by their position 
and their according class of factor, and constructs matrices from these sets representing the 
prediction [Grabe, 2002]. 
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3.6. Statistical methods 
P-values were calculated using the scientific analysis and presentation computer program 
“Graph Pad Prism 4.0/5.0”. Significance was calculated by unpaired, two-tailed t test 
[C.I.=95%]; the significance levels were set at ***p≤0.001, **p≤0.01, and *p≤0.05. 
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4. Results 
4.1. Identification of OPG gene variants and molecular promoter 
haplotypes (MolHaps) 
In initial studies, the 5’-flanking region, exons, introns, and the 3’-flanking region of the OPG 
gene were scanned for alterations in genomic DNA from 95 patients of the ECTIM study. 
ECTIM (Etude Cas-Témoins de l'Infarctus du Myocarde ) is a study of patients with MI from 
regions covered by the World Health Organization’s Monitoring Trends and Determinants in 
Cardiovascular Disease (MONICA) registers and of control subjects (cases [n=988, 
mean±SD age 55.8±8.1 years, 26.2% women], controls (n=949, mean±SD age 56.6±8.3, 
27.0% women]) [Cambien et al, 1992]. Altogether, 9 SNPs were identified, three of which 
were located in intronic regions (C1217T, Ins/Del/ct 6533/34, A8731C), two polymorphisms 
were found in exonic regions (one non-synonymous SNP in exon 1 [K3N], one synonymous 
SNP in exon 4 [A+832G]), and four SNPs located in the OPG gene promoter region (one 
proximal variant [T-159C] and three distal variants [A-946G, G-900A, T-864G]) (Figure 14). 
Of the 5’-flanking region of the OPG gene, a portion of 275 bp bearing the T-159C (-287/-13) 
variant and a portion of 249 bp covering SNPs A-946G, G-900A, T-864G (-1020/-772) were 
amplified in an additional set of genomic DNA of 57 patients with MI and/or essential 
hypertension (MolProMD study). All polymorphisms of the 5’-flanking region, detected in the 
ECTIM study, were also found in patients of the MolProMD study. Further, polymorphism 
T-960C was identified exclusively in probes of the MolProMD study. All polymorphisms had 
previously been identified [Arko et al, 2002; Rhee et al, 2006; Langdahl et al, 2002; 
Brändström et al, 2002; Soufi et al, 2004]. 
 
 
 
 
 
Figure 14 Schematic representation of the OPG gene architecture. The promoter, the 3’- and 
5’-untranslated regions (dashed bars), the exons (blank bars), the major transcription start site (arrow), 
and the translation termination codon (asterisk) are indicated. Identified SNPs are indicated, for rs 
numbers see appendix, Table 1. 
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Figure 15 Sequence analyses of genomic DNA of 57 MolProMD patients. (A) Alleles TT, TC, 
and CC for -159; (B) homozygotic and heterozygotic occurrence for SNPs T-960C, A-946G, G-900A, 
T-864G. 
The proximal polymorphism T-159C was found to be the most frequent variant occurring in 
72.72% of the patients (CC [18.18%], TC [54.54%]). The homozygous wild type allele (TT) 
was found in 27.27% (Figure 15A). The distal SNPs T-960C, A-946G, G-900A, T-864G were 
found to be transmitted either homozygously for the common alleles (-960T, -946A, -900G, 
-864T) or heterozygously (-960TC, -946AG, -900GA, -864TG). Further, while alleles -946A 
and -946G were observed to be transmitted with the major alleles -960T, -900G, and -864T, 
A
B
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alleles -960TC, -900GA, -864TG where only transmitted in the presence of each other, and 
in the presence of -946A and -946G (Figure 15B). 
 
To identify molecular promoter haplotypes (MolHaps) harboring SNPs T-960C, A-946G, 
G-900A, and T-864G, genomic DNA from 57 patients of the MolProMD study were screened. 
A 249 bp fragment (-1020/-772 portion of the OPG promoter) was amplified, subcloned, and 
sequenced in both directions. Three common molecular haplotypes were identified: 
OPG-MolHap1 (wt) bearing no variant and representing the most frequent haplotype 
(78.9%); OPG-MolHap2 [T-960- G-946- G-900- T-864] occurring in 12.3% of the MolProMD 
patients, and OPG-MolHap4 [C-960- G-946- A-900- G-864] being the least frequent haplotype with 
8.8% of occurrence. Noteworthy, as described above, alleles -960C, -900A, and -864G were 
always transmitted in the same haplotypic background (Figure 16). 
 
 
 
 
 
 
 
 
Figure 16 Molecular haplotypes of the human OPG promoter region. Haplotypes OPG-MolHap1 
(wt), OPG-MolHap2 and OPG-MolHap4 were subcloned (-1020/-772 portion of the human OPG 
promoter) into the reporter gene vector ptk81-luc3, which harbors a minimal viral promoter. 
 
4.2. In silico analysis of putative TFBS in the OPG promoter 
Analyses of the molecular promoter haplotypes OPG-wt, OPG-MolHap2, and OPG-MolHap4 
with the net-based program Alibaba 2.1 predicted several putative TFBS, some of which 
were altered in the presence of respective nucleotide substitutions. OPG-wt, OPG-MolHap2 
[T-960, G-946, G-900, T-864] and OPG-MolHap4 [C-960, G-946, A-900, G-864] showed a sequence 
similarity for NF-κB, a beta scaffold transcription factor with minor groove contact harboring a 
Rel homology region. For both, OPG-MolHap2 and OPG-MolHap4, the -946A allele 
represents a putative binding site for transcription factor Sp1 (specificity protein 1), belonging 
to the family of ubiquitous factors bearing a Cys2His2 zinc finger domain (Figure 17A). This 
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binding pattern is lost for the minor -946G allele. Further, the -960C allele of OPG-MolHap4 
is a putative binding sequence for the family of NF-1 transcription factors, which is lost for the 
-960T allele (Figure 17B). Members of the NF-1 family are transcription factors originally 
identified as essential for DNA replication by adenoviruses [Nagata et al, 1982]. They play 
important roles in mammary gland function and development [Jones et al, 1987]. In contrast, 
alleles -900A and -864G did not alter predicted binding motifs when compared to major 
alleles. 
 
 
 
 
 
 
 
 
 
Figure 17 Transcription factor binding sites (TFBS). (A) TFBS for OPG-MolHap2 (B) for 
OPG-MolHap4. Analyses were performed using AliBaba 2.1. Major alleles are marked in red, minor 
alleles are in blue. Potential transcription factors are marked in red and blue, accordingly. Factors 
binding both, major and minor alleles, are marked in black. 
 
The genomic area flanking T-159C predicted several putative and partly overlapping TFBS, 
but no physical TFBS was predicted for the position of the variant itself (Figure 18). 
Interestingly, 68 bp upstream of T-159C two “clusters” of TFBS with repetitive binding sites of 
Sp1, AP-2, and early growth response-1 (Egr1) occur. Members of the Egr family of 
transcription factors contain three repetitive zinc finger DNA binding domains. 
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Figure 18 Transcription factor binding sites (TFBS) in sequence flanking SNP T-159C. 
Analyses were performed using AliBaba 2.1. Major allele is marked in red, minor allele in in blue. 
Potential transcription factors are marked in red and blue, accordingly. Factors binding both, major and 
minor allele, are marked in black. Allele-specific TFBS were not predicted. 
 
4.3. Endogenous OPG expression 
Since it has been shown that OPG mRNA and protein levels are regulated, among other 
factors, by 17β-Estradiol and TNFα [Hofbauer et al, 1998; Hofbauer et al, 1999], cells were 
stimulated with TNFα (2 ng/mL, 6 hrs), 17β-Estradiol (10-8M, 24 hrs), or both. To detect 
endogenous OPG expression at both transcript and protein level, semi-quantitative PCR 
using a specific intron-spanning primer set for the OPG coding region, and Western Blot 
analyses were performed using a specific antibody against OPG. OPG mRNA expression 
was evenly detectable in both SaOs-2 and U2Os cells with and without stimulation. Likewise, 
OPG protein was detectable in both cell lines under all stimulatory regimes (Figure 19). No 
differences in OPG mRNA and immunoreactive protein expression were detectable after 
stimulation with TNFα, 17β-Estradiol, and both. Therefore, all following experiments were 
performed under basic conditions. 
ccaccgccccacccctcacgccccacctccctgggggatcctttccgccccagccctgaaagcgttaa tc cctggagctttctgcacaccccccgaccgctcccgcccaagcttcctaaaaaagaaa
===Egr1==
====Sp1======
=AP-2alph=
====Sp1===
====Sp1===
==Olf-1===
====Sp1===
==Egr1===
=AP-2alph=
===Sp1==
=RXRbeta=
====Sp1=====
===Sp1===
===Sp1====
==LyF-1==
-159
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Figure 19 Endogenous OPG expression. Endogenous OPG mRNA and protein expression in 
SaOs-2 and U2Os cells stimulated with TNFα (T; 2 ng/mL, 6 hrs), 17β-Estradiol (E2; 10-8M, 24 hrs), 
and both TNFα and 17β-Estradiol (T/E2). Semi-quantitative PCR was performed with a specific primer 
set for OPG and hRP27 (upper panel), the latter serving as control for the PCR experiment. OPG 
protein was detected using a specific antibody (lower panel). 
 
Bioactivity of TNFα and 17β-Estradiol was tested in dose-response assays by reporter gene 
assay with plasmids harboring TNFα responsive elements (pNFκB-TA/luc) and estrogen 
responsive elements (pERE2-tk/luc) linked to the luciferase gene. HEK293T und MCF-7 cells 
were used as reference cell lines, respectively. Stimulation with 2 ng/mL TNFα (6 hrs) 
resulted in a significant increase of pNFκB-TA/luc activity in both cell lines (SaOs-2: 3.45-fold 
induction over basic conditions, p=0.0012; HEK293T: 8.82-fold induction over basic 
condition, p<0.0001). Increasing TNFα concentration did not alter pNFκB-TA/luc activity 
(Figure 20A). Stimulation of estrogen receptor (ER) α and β positive MCF-7 breast cancer 
cells with 17β-Estradiol (24 hrs) resulted in a classical ER-mediated dose-response curve of 
the activity of pERE2-tk/luc, with 10-9M being the optimal concentration (2.4-fold induction 
over basal conditions, p=0.0017). In contrast, SaOs-2 did not respond to 17β-Estradiol 
stimulation (Figure 20B), probably due to the absence of ERα in this cell line (Figure 20C) 
[Hillebrand et al, 2009]. 
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Figure 20 Dose-response curves for TNFα and 17β-Estradiol. (A) Dose-response curve for 
TNFα in SaOs-2 and HEK293T. Both responded to TNFα stimulation (6 hrs). (B) Dose-response curve 
for 17β-Estradiol (24 hrs) in SaOs-2 and MCF-7 cells, the latter displayed a classical dose-response 
curve, while SaOs-2 did not respond to any 17β-Estradiol concentration. (C) Detection of 
immunoreactive ERα (upper panel) and ERβ (middle panel) in MCF-7 and SaOs-2 cells. Samples’ 
even loading was ascertained using a specific antibody against MAPK2 (lower panel). 
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4.4. Alternative transcription start sites (TSS) of the OPG gene 
Preference for TSS is often tissue- and cell type-specific, therefore the focus was set on 
SaOs-2 and U2Os cells to determine osteosarcoma-typical TSS. The OPG gene is 
transcribed into four transcripts (2.4 kb, 3.0 kb, 4.2 kb, and 6.5 kb in length). The 4.2 kb and 
6.5 kb transcripts result from alternative splice-events in intron 2, while the 2.4 kb and 3.0 kb 
transcripts result from the alternative usage of transcription start sites (TSS, Figure 21A) 
[Morinaga et al, 1998]. Using RACE, we identified two TSS in both cell lines. TSS1 is located 
64 bp upstream of the ATG codon (position 1109 in Acc# AB008822), while TSS2 is located 
225 bp upstream of the ATG codon (position 948 in Acc# AB008822). We confirmed these 
results by diacritic PCR with specific primers, located directly at the respective TSS. In 
SaOs-2, both TSS were utilized equally, while in U2Os transcription is mainly driven from 
TSS1. Further, we defined a third TSS (TSS3, 667 bp upstream of the ATG codon, position 
506 in Acc# AB008822) by diacritic PCR in both cell lines. TSS3 is utilized as frequent as 
TSS1 in both cell lines, and has already been described by Morinaga and colleagues (Figure 
21B) [Morinaga et al, 1998]. Transcription from TSS1 and TSS2 results in the 2.4 kb 
transcript, while transcription started at TSS3 results in the 3.0 kb transcript. As TSS1 is 
usually described as major TSS, positions of SNPs are indicated relative to this site. 
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Figure 21 Alternative TSS of the OPG gene. (A) Schematic representation of the alternative TSS 
of the OPG gene. The 5’UTR (dashed box), coding region (blank box), and TSS (right-tangled arrows) 
are indicated. (B) 740 bp of the OPG sequence (bp 442-1181, Acc# AB008822). 5’-flanking region 
(lower case), exon 1 (upper case), alternative TSS 1-3 (bold, arrows), and the ATG codon (underlined, 
asterisk) are indicated. (C) Diacritic PCR for verification of the detected TSS. In SaOs-2 all detected 
TSS are used equally, while in U2Os TSS2 is used less frequent. 
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4.5.  OPG promoter constructs 
For characterization of the OPG promoter region and identification of regulatory sequences 
by deletion constructs, the focus was set on analyzing the detected promoter variants. A 
sufficiently active promoter portion (1008 bp) of the OPG gene in osteosarcoma cell lines is 
termed full length construct for this study. Serial deletion constructs were generated (Figure 
23A) and the detected variants were analyzed in the context of both, the full length 
constructs (Figure 23B) and the deletion constructs (Figure 23C). According to the identified 
haplotypes (4.1), 249 bp (-1020/-772) flanking OPG-wt, MolHap2, and MolHap4 were linked 
into reporter gene vector ptk81-luc3 (Figure 22A). In addition, 275 bp flanking T-159C were 
linked to reporter gene vector pGL3basic (Figure 22B). 
 
 
 
 
 
 
 
 
 
 
 
Figure 22 Reporter gene constructs of OPG MolHaps and -159. (A) Sequences flanking the 
identified molecular haplotypes (-1020/-772) were linked to reporter gene vector ptk81-luc3, harboring 
a minimal promoter. (B) 275 bp spanning T-159C were linked to promoter-less reporter gene vector 
pGL3basic. Common alleles (with boxes) and less frequent alleles (black boxes) are indicated. 
 
4.6. Reporter gene assays 
4.6.1. OPG promoter analyses with full length constructs 
The identified SNPs were introduced in the context of the commonly occurring MolHaps into 
the full length constructs (-1020/-13), and transient transfection assays in SaOs-2 and U2Os 
cells were performed.  
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Figure 23  Schematic presentation of OPG 5’-flanking region. (A) Design of deletion constructs, 
positions of antisense (AS) and respective sense primers (S1–S4) are indicated. (B) Detected variants 
in haplotypic constellation in the context of the full length construct, and (C) in the context of the 
5’-truncated constructs. Common alleles (white boxes) and less frequent alleles (black boxes) are 
indicated. 
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In both cell lines, the wt full length construct (OPG-Del1) was sufficiently active, and 
transcriptional activity was significantly decreased for both MolHap2 (OPG-D1H2 [SaOs-2: 
0.63-fold activity over wt, p=0.0014; U2Os: 0.69-fold activity over wt, p=0.0018]), and 
MolHap4 (OPG-D1H4 [SaOs-2: 0.43-fold activity over wt, p<0.0001; U2Os: 0.59-fold activity 
over wt, p=0.0011]). Transcriptional activity was further significantly decreased for OPG-wt 
and MolHap2, when the -159C allele was introduced into the respective full length constructs 
(OPG-Del1-159c [SaOs-2: 0.53-fold activity over OPG-Del1, p<0.0001; U2Os: 0.71-fold 
activity over OPG-Del1, p=0.0014], OPG-D1H2-159c [SaOs-2: 0.65-fold activity over 
OPG-D1H2, p=0.0058; U2Os: 0.71-fold activity over OPG-D1H2, p=0.0029]). Presence of 
the -159C allele in the MolHap4 full length construct resulted in a slight, but not significant 
decrease of transcriptional activity (OPG-D1H4-159c [SaOs-2: p=0.2749; U2Os: p=0.9989]) 
(Figure 24). 
 
4.6.2. Serial deletion analyses 
To define regions involved in the transcriptional activity of the OPG promoter, deletion 
constructs of the OPG 5’-flanking region were generated (Figure 23A). Reporter vector 
pOPG-Del1/luc represents the full length construct (1008 bp) with “wild type” sequence [T-960- 
A-946- G-900- T-864- T-159]. All following constructs were 5’-truncated, each harboring “wild type” 
sequences: pOPG-Del2/luc (924 bp [G-900- T-864- T-159]), pOPG-Del3/luc (665 bp [T-159]), and 
pOPG-Del4/luc (275 bp [T-159]). As shown in Figure 25, pOPG-Del1/luc displayed a sufficient 
transcriptional activity in both cell lines. Truncation of 84 bp (-1020/-936) resulted in a 
complete abrogation of transcriptional activity (pOPG-Del2/luc, p<0.0001), indicating a 
cis-active element within. Further, truncated constructs pOPG-Del3/luc (-936/-677) and 
pOPG-Del4/luc (-677/-287) did not restore and transcriptional activities remained silent at the 
level of empty vector pGL3basic. 
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Figure 24 Transient transfection assays with full length reporter gene constructs harboring 
the identified SNPs in the context of the MolHaps. Common alleles (white boxes) and less frequent 
alleles (black boxes) are indicated at the corresponding promoter positions. In both, U2Os and 
SaOs-2, presence of the -159C allele reduced the transcriptional activities of the MolHaps, for OPG-wt 
(OPG-Del1) and MolHap2 (OPG-D1H2) to a significant extend (***, p≤0.001; **, p≤0.01; *, p≤0.05; ns, 
not significant). 
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Figure 25 Transcriptional activities of OPG promoter deletion constructs. SaOs-2 and U2Os 
cells were transfected with OPG deletion constructs. The full length construct (OPG-Del1) displayed a 
sufficient transcriptional activity, whereas activities of remaining constructs were below of that of the 
full length construct (p<0.0001 for both cell lines) (***, p≤0.001; **, p≤0.01; *, p≤0.05; ns, not 
significant). 
 
Truncation of the full length construct by 84 bp (-1020/-936) resulted in significantly 
decreased transcriptional activity in both cell lines (OPG-Del2, p<0.0001). Introduction of the 
-159C allele increased activity (OPG-Del2-159c [SaOs-2: 3.9-fold activity over OPG-Del2, 
p=0.0005; U2Os: 1.76-fold activity over OPG-Del2, p<0.0001]). Likewise, transcriptional 
activities were significantly increased in both cell lines for OPG-Del3 (OPG-Del3-159c 
[SaOs-2: 5.6-fold activity over OPG-Del3, p<0.0001; U2Os: 6.2-fold activity over OPG-Del3, 
p<0.0001]), and OPG-Del4 (OPG-Del4-149c [SaOs-2: 5.9-fold activity over OPG-Del4, 
p<0.0001; U2Os: 4.4-fold activity over OPG-Del4, p<0.0001]), when the -159C allele was 
introduced into the respective constructs (Figure 26 and Figure 27), indicating a repressive 
effect of the -159C allele on OPG gene transcription. 
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Figure 26 The -159C allele increases transcriptional activity of OPG in the context of the 
promoter deletion constructs. Transient transfection assays with deletion constructs harboring the 
identified SNPs in context of the MolHaps. Common alleles (white boxes) and less frequent alleles 
(black boxes) are indicated at the corresponding promoter positions. In SaOs-2, and in contrast to the 
full length promoter constructs, transcriptional activities of the deletion constructs (OPG-Del2, 
OPG-Del3, OPG-Del4) were significantly increased, when the -159C allele was introduced into the 
constructs (***, p≤0.001; **, p≤0.01; *, p≤0.05; ns, not significant). 
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Figure 27 The -159C allele increases transcriptional activity of OPG in the context of the 
promoter deletion constructs. Transient transfection assays with deletion constructs harboring the 
identified SNPs in context of the MolHaps. Common alleles (white boxes) and less frequent alleles 
(black boxes) are indicated at the corresponding promoter positions. In U2Os, and in contrast to the 
full length promoter constructs, transcriptional activities of the deletion constructs (OPG-Del2, 
OPG-Del3, OPG-Del4) were significantly increased, when the -159C allele was introduced into the 
constructs (***, p≤0.001; **, p≤0.01; *, p≤0.05; ns, not significant). 
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4.6.3. OPG promoter analyses with MolHaps and T-159C separately 
To investigate the transcriptional activity of the three MolHaps and T-159C separately, the 
-1020/-772 portion of the human OPG 5’-flanking region was linked to the reporter gene 
vector ptk81-luc3, which contains a minimal promoter allowing for the assembly of the 
transcriptional machinery, with only very little remnant activity. As shown in Figure 28A, in 
both cell lines, the OPG-wt displayed poor transcriptional activity, being as active as the 
mock vector ptk81-luc3. As seen in the context of the full length constructs, a highly 
significant decrease of transcriptional activity occurred for MolHap2 (SaOs-2: 0.07-fold 
activity over the wt, p=0.0027; U2Os: 0.08-fold activity over the wt, p<0.0001) and MolHap4 
(SaOs-2: 0.34-fold activity over the wt, p=0.0097; U2Os: 0.51-fold activity over the wt, 
p=0.0006). This isolated promoter portion comprising the three MolHaps, seemed to be 
poorly involved in the transcriptional momentum of OPG (0.5-fold induction over mock 
vector). Likewise, a 275 bp portion (-287/-13) of the 5’-flanking region, harboring the either 
-159T or -159C allele was linked to the promoter-less reporter gene vector pGL3basic and 
transient transfections were performed. In both cell lines, the reporter gene construct 
OPG-159T displayed a weak transcriptional activity at the level of the empty vector. The 
construct carrying the -159C allele (OPG-159C) revealed a significant increased activity 
(SaOs-2: 12.7-fold activity over OPG-159T, p=0.0001; U2Os: 2-fold activity over OPG-159T, 
p=0.0002) (Figure 28B). 
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Figure 28 Reporter gene assays in SaOs-2 and U2Os. (A) Isolated MolHaps (pOPG-wt/luc, 
pOPG-MolHap2/luc, and pOPG-MolHap4/luc). In both cell lines, OPG-wt displayed a weak basal 
activity, less than the empty vector ptk81-luc3. Transcriptional activities were again significantly lower 
for MolHap2 (SaOs-2: 0.07-fold activity over wt, p=0.0027; U2Os: 0.08-fold activity over wt, p<0.0001) 
and MolHap4 (SaOs-2: 0.34-fold activity over wt, p=0.0097; U2Os: 0.51-fold activity over wt, 
p=0.0006). (B) Transient transfections with constructs carrying either the -159T or -159C allele. In both 
cell lines, presence of the -159C allele significantly increased transcriptional activity of the -287/-13 
portion (SaOs-2: p=0.0001, U2Os: p=0.0002) (***, p≤0.001; **, p≤0.01; *, p≤0.05; ns, not significant). 
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4.7. Electrophoretic Mobility Shift Assays (EMSA) 
To investigate DNA:protein interactions of the OPG promoter fragments, EMSAs were 
performed with SaOs-2 and U2Os nuclear protein extracts. Either PCR amplicons (154 bp, 
3’-biotinylated) harboring OPG-wt, OPG-MolHap2, or OPG-MolHap4, or oligonucleotides 
(30 bp, 3’-biotinylated) containing the T-159C variant, served as probes, and were competed 
with an unlabeled PCR fragment in a 200-fold molar excess. In case, probes were competed 
with oligonucleotides harboring consensus sites for Sp1, NF-1, or Egr1 with a 200-fold molar 
excess. 
 
4.7.1. SaOs-2 and U2Os nuclear extracts interact with OPG MolHaps 
SaOs-2 nuclear extracts revealed a specific shift for all three MolHaps, being less 
pronounced for MolHap2 and MolHap4 (Figure 29, black arrow). In addition, a weak band 
was visible for MolHap2 and MolHap4, being competed with the unlabeled PCR fragment 
(Figure 29, open arrows). A similar binding pattern was observed with U2Os nuclear 
extracts. A distinct, specific shift for OPG-wt and OPG-MolHap4, being less intense for the 
latter was detected (Figure 29, open arrows). 
 
 
 
 
 
 
 
 
 
 
Figure 29 SaOs-2 and U2Os nuclear extracts interact with OPG MolHaps. Binding was 
competed with an unlabeled PCR fragment. In SaOs-2, specific shifts were detected for all three 
MolHaps (black arrow). Further, a semi allele-specific shift was detected for MolHap2 and MolHap4 
(open arrow). In U2Os a semi allele-specific shift was detected for OPG-wt and MolHap4 (open 
arrow).  
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There was no specific binding pattern for MolHap2. The additional binding for MolHap2 and 
MolHap4 found in SaOs-2 cells was lost. Since in silico analyses predicted altered binding 
sites for transcription factors Sp1 and NF-1 (Figure 17), we performed EMSAs using the 
respective consensus sites as competitors. In SaOs-2, the prominent band (Figure 30, black 
arrow) was completely competed for all three MolHaps by NF-1, but not by Sp1 consensus 
oligonucleotides. The above described binding pattern for MolHap2 and MolHap4 was 
completely competed by a Sp1 consensus site (Figure 30, open arrows). In U2Os, the 
specific shift for OPG-wt and OPG-MolHap4 was completely competed with NF-1, but not by 
Sp1 consensus oligonucleotides (Figure 30, black arrow). 
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Figure 30 NF-1 and Sp1 interact with OPG MolHaps. Binding was competed with unlabeled 
consensus sites for Sp1 and NF-1 in a 200-fold molar excess. Free probe, specific binding of the three 
MolHaps (black arrow), and semi allele-specific binding of MolHap2 and MolHap4 (open arrows) are 
indicated. 
 
4.7.2. The -159T allele is specifically bound by nuclear proteins from 
SaOs-2 and U2Os cells 
EMSAs performed with nuclear extracts from unstimulated SaOs-2 cells resulted in an 
allele-specific shift for the major -159T allele, which was specifically competed with unlabeled 
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oligos. This binding pattern was lost, when EMSAs were performed with oligonucleotides 
bearing the -159C allele. In fact, we could not detect any specific protein binding pattern for 
the OPG -159C allele, the same being observed with nuclear extracts from U2Os cells 
(Figure 31, black arrows). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 31 The -159T allele is specifically bound by nuclear proteins from SaOs-2 and U2Os 
cells. EMSAs with 30 bp oligonucleotides containing T-159C were performed with 5 µg of nuclear 
protein extracts from SaOs-2 and U2Os. The -159T allele displayed an allele-specific shift in both cell 
lines (black arrow).  
 
Even though in silico analyses (Figure 18) did not predict altered TFBS for T-159C, EMSAs 
were performed using Sp1 and Egr1 consensus sites as competitor. These transcription 
factors are grouped in “clusters” of TFBS 68 bp upstream of T-159C. The prominent -159T 
binding pattern was competed with an Egr1 consensus site in SaOs-2 and U2Os cells, but 
not with a Sp1 consensus site (Figure 32A). Additionally, we incubated probes with 
recombinant Egr1 binding domain and detected specific binding exclusively to the -159T 
allele. A biotinylated Egr1 consensus site served as control (Figure 32B). 
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Figure 32 Egr1 binds specifically to the -159T allele. (A) EMSA was performed with -159T using 
Sp1 and Egr1 consensus sites for competition. The allele-specific band was competed with an Egr1, 
but not with a Sp1 consensus site (black arrow). (B) EMSA performed with labeled oligonucleotides 
harboring either the -159T or -159C allele and purified Egr1 binding domain (Egr1-BD). Egr1 binds 
exclusively to the -159T, not to the -159C allele (black arrow). 
 
4.7.3. Co-transfections and ChIP 
4.7.3.1. OPG MolHaps 
Using an unlabeled NF-1 consensus site in EMSA experiments, a specific interaction of NF-1 
with the OPG-MolHaps was observed. To identify the interacting individual members of the 
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NF-1 family of transcription factors, co-transfections with expression vectors for NF-1/A1.1, 
NF1/B2, NF1/C2, and NF1/X2 were performed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 33 MolHaps in the context of the full length construct co-transfected with expression 
vectors of the NF-1 protein family. NF-1/A1.1 reduced transcriptional activity significantly for all 
three MolHaps in U2Os, and for OPG-wt in SaOs-2. NF-1/B2 increased transcriptional activity in both 
cell lines, significantly for MolHap2 and MolHap4 in SaOs-2, and MolHap2 in U2Os (***, p≤0.001; **, 
p≤0.01; *, p≤0.05; ns, not significant). 
 
Co-transfection with NF-1/A1.1 revealed significant decreases of transcriptional activities of 
OPG-wt, MolHap2, and MolHap4 in U2Os cells (p=0.0138, p=0.0002, p=0.012, respectively). 
In SaOs-2 cells, only OPG-wt displayed a significantly decreased transcriptional activity 
when co-transfected with NF-1/A1.1 (p=0.013). Co-transfection with NF-1/B2 resulted in 
increased transcriptional activities, significantly for MolHap2 (p=0.02) and MolHap4 
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(p=0.0001) in SaOs-2 cells, and MolHap2 (p<0.0001) in U2Os cells. NF-1/C2 and NF-1/X2 
did not alter transcriptional activity in any cell line (Figure 33).  
Further, we performed ChIP assays with specific antibodies against Sp1, Egr1, and NF-1. In 
U2Os cells, we found transcription factor NF-1 bound to the sequence spanning SNPs 
T-960C, A-946G, G-900A, T-864G; this binding was completely absent for this promoter 
portion in SaOs-2 cells (Figure 34). 
 
 
 
 
 
 
 
 
 
 
Figure 34 ChIP assay performed in SaOs-2 and U2Os cells. Precipitated DNA was amplified with 
specific primers covering T-960C, A-946G, G-900A, T-864G (bp -992/-839). In SaOs-2 cells, we could 
not detect any binding of Sp1, NF-1, or Egr1 to the distal -992/-839 portion. In U2Os cells, binding of 
transcription factor NF-1 was slightly detectable. 
 
4.7.3.2. OPG T-159C 
Since in silico analyses predicted combined binding sites for Sp1 and Egr1 68 bp upstream 
the T-159C (Figure 18), co-transfection analyses with expression vectors for Sp1 and Egr1 
were performed (Figure 35A). Overexpression of Sp1 resulted in significantly increased 
transcriptional activities for OPG-Del1 (SaOs-2: 13.3-fold induction over empty expression 
vector, p<0.0001; U2Os: 18.14-fold induction over empty expression vector, p<0.0001) and 
OPG-D1-159c (SaOs-2: 7.5-fold induction over empty expression vector, p=0.0002; U2Os: 
21.17-fold induction over empty expression vector, p<0.0001). 
 
By contrast, overexpression of Egr1 resulted in significantly decreased transcriptional 
activities for both constructs, supporting the suggested repressing effect of Egr1 in OPG 
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gene regulation (OPG-Del1, SaOs-2: 0.43-fold induction over empty expression vector, 
p=0.0011; U2Os: 0.36-fold induction over empty expression vector, p=0.0003). Remarkably, 
this repressive effect was less pronounced for the -159C allele (OPG-Del1-159c, SaOS-2: 
0.6-fold induction over empty expression vector, p=0.0014; U2Os: 0.46-fold induction over 
empty expression vector, p=0.0148). In addition, and as described above, ChIP assays with 
specific antibodies were performed. In SaOs-2, binding of Sp1 and a weak interaction of 
NF-1 with the T-159C spanning sequence (-288/-38) was detected. Similar results were 
obtained, when ChIP was performed in U2Os; Egr1 and NF-1 were found to bind -288/-38 
portion of the OPG 5’-flanking region (Figure 35B). 
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Figure 35 Egr1 interacts with the -288/-38 OPG promoter portion. (A) Co-transfection analyses 
of the full length construct harboring either the -159T allele (OPG-Del1) or the -159C allele 
(OPG-Del1-159C) with expression vectors for Sp1 and Egr1. Sp1 increased transcriptional activity of 
both constructs (white dashed bar). Overexpression of Egr1 resulted in a significant decreased 
transcriptional activity for OPG-Del1 (-159T allele), being less intense for -159C allele carrying full 
length construct (grey dashed bar) (***, p≤0.001; **, p≤0.01; *, p≤0.05; ns, not significant). (B) 
Precipitated DNA was amplified with specific primers located in the 5’-flanking region of the OPG gene 
promoter, covering the proximal variant T-159C (bp -288/-38). In SaOs-2 cells, binding of Sp1 was 
slightly detectable, while in U2Os cells binding of transcription factors Egr1 and NF-1 was detectable. 
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5. Discussion 
In the present study, 5 genetic variants within the 5’-flanking region of the human OPG gene 
were analyzed: T-960C, A-946G, G-900A, T-864G, and T-159C. Sequences relevant for 
transcriptional regulation were analyzed as well as individual transcriptional consequences of 
the respective variants. Only few studies aimed at characterizing the OPG promoter region 
and very little is known about the molecular basis of its transcriptional regulation. Therefore, 
the focus was set on promoter analyses. In this study, a portion of 1008 bp was found to be 
sufficiently active and used for further promoter studies. A series of truncated promoter 
constructs was generated for both the identification and characterization of regulatory 
elements. A portion of 84 bp (bp -1020/-936) was found to be essential for transcriptional 
activity in tested osteosarcoma cell lines SaOs-2 and U2Os. 
 
5.1. Alternative TSS of the OPG gene 
Transcription of the OPG gene was shown to start at multiple TSS [Morinaga et al, 1998]. As 
known so far, the usage of alternative TSS in the OPG gene results in varying lengths of the 
transcripts, of the 5’ untranslated region (5’UTR). In the present study, we first analyzed the 
transcriptional organization of the OPG promoter by 5’ RACE, which led to the identification 
of one novel TSS 225 bp upstream of the ATG codon (TSS2, position 948 in Acc# 
AB008822). We then defined a TSS 64 bp upstream of the ATG codon (TSS1, position 1109 
in Acc# AB008822) very close to the major TSS described by Morinaga et al. Authors 
reported a major TSS 67 bp upstream of the ATG codon, by primer extension with 
[γ-32P]dCTP end-labeled primers. Given the very short difference (3 bp) between these two 
major TSS (67 bp and 64 bp upstream of the ATG codon), a technical inaccuracy rather than 
the actual presence of two separate TSS is presumable. In this respect, radioactive end-
labeling of oligonucleotides often causes decompositions of the probe by radiation, leading 
to a possibly imprecise mapping of the TSS. Transcription from TSS1 and TSS2 results in a 
2.4 kb transcript, which is the major transcript detectable in all OPG expressing tissues 
[Morinaga et al, 1998]. We further mapped a third TSS (TSS3, 667 bp upstream of the ATG 
codon, position 506 in Acc# AB008822) by use of diacritic PCR, which has been described 
previously. Transcription from TSS3 results in a 3.0 kb transcript, found in brain, placenta, 
spleen, and prostate [Yasuda et al, 1998]. Since the 3.0 kb transcript is tissue-specific, it is 
possible that transcription of the OPG gene is under control of two alternative promoters, 
activated by tissue-specific transcription factors. Alternative promoter usage is a common 
phenomenon, and on average 3.1 promoters are suggested per gene [Cheong et al, 2006]. 
In silico analyses of the OPG 5’-flanking region predicted two promoter regions, each 
harboring a TATA box in spatial vicinity of TSS1 and TSS3 (data not shown) [Center for 
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Information Technology]. As mentioned above, transcription started from the different TSS of 
the OPG gene will not alter the generated protein, but result in mRNA isoforms with 
heterogeneous 5’UTR, which may influence transcript stability and/or translation efficiency. 
 
5.2. Genetic variants alter OPG promoter performance 
Genetic variants within the promoter region may influence promoter activity when located in 
or near cis-active elements [Telgmann et al, 2008]. Quantification of differential 
transcriptional activities of a given DNA sequence by reporter gene assays depends on three 
items. Firstly, the basic transcription machinery needs to assemble. Secondly, variances 
within the provided sequence (wt or variant) may result in differential transcriptional activity, 
and thirdly, the introduction or presence of a Kozak-sequence or one or more TSS might 
lead to differences in transcript stability or expression [Heintzman and Ren, 2006; Ross, 
1995]. Specific expression patterns are defined by cis-active elements that direct 
transcription by interplay with the core promoter [Lemon and Tjian, 2000]. Genetic variants 
within these regulatory regions may alter binding affinity of TF to their consensus DNA 
sequence, thereby affecting gene transcription and expression patterns. 
Potential effects of the detected promoter variants were analyzed within a 1008 bp portion of 
the OPG promoter (-1020/-13) by measuring transcriptional activities under basal conditions. 
As expected, this promoter portion was sufficiently transcriptionally active. In bone, the 
relative expression of OPG and RANKL is critical for osteoclastogenesis and therefore 
critical for the regulation of skeletal mass, structure, and strength. Hence, a moderate 
transcriptional activity of the OPG gene under basic conditions, to not disequilibrate the 
osteoclast-osteoblast ratio, seems conceivable. Over the past years, there has been an 
emerging awareness that gene transcription can be regulated by cis-acting elements located 
at considerable distances, up to 1000 kb, from the gene they control [Higgs et al, 2008]. 
Therefore, the analyzed 1008 bp OPG promoter portion may not be considered as the entire 
OPG promoter, rather as a part of it, but being sufficient for OPG gene transcription in 
osteosarcoma cells. Nevertheless, transcriptional activities of MolHap2 and MolHap4 either 
in the context of the full length construct, or separately were significantly decreased when 
compared to the wt. In contrast to haplotypes estimated by maximum likelihood (ML) method 
of inference [Tregouet et al, 2002] or other tools, MolHaps are inferred from subcloning 
procedures of individual DNA providing the exact allelic constellations in a given DNA strand, 
which might be crucial information with respect to differential haplotypic function [Duan et al, 
2003; Dördelmann et al, 2008]. In addition, introduction of the -159C allele into the 
respective full length construct further decreased transcriptional activities. As mentioned 
above, genetic variants within regulatory sequences may alter TFBS, or rather the binding 
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affinity for TFs. Altered binding affinities of TFs caused by the OPG promoter variants may 
cause the observed differences in transcriptional activities of the OPG promoter constructs. 
 
5.3. Alterations of DNA:protein binding patterns 
TFs act as transcriptional modules consisting of at least two proteins. Primarily, binding of 
TFs depends on the interaction/recognition of the electrostatic environment of the DNA 
sequence/TFBS they bind to, and on the stoichiometric availability of the TFs participated in 
the module. Other than in coding regions, TFBS are composed of a DNA sequence in which 
each position is of different importance and relevance for the molecular function of the entire 
site. Therefore, alterations of TFBS by SNPs may cause an altered affinity of the respective 
TF binding, rather than a complete loss of the binding performance. Further, the preference 
to recruit a certain TF to a given module depends on the affinity of the recruiting factor. Since 
computational predictions cannot integrate the physiological state of a cell and neither the 
impact of protein:protein binding affinities on the recruitment of factors to a transcriptional 
module, they fail to comprehensively predict protein binding for MolHap constellations.  
 
5.3.1. OPG MolHaps 
In silico analyses of the sequence spanning the OPG MolHaps revealed a binding site for 
Sp1 for the major -946A allele. This binding pattern is lost with the occurrence of the minor 
-946G allele, in MolHap2 and MolHap4. EMSA experiments revealed an allele-specific 
interaction of MolHaps 2 and 4 with Sp1 in SaOs-2. In U2Os no interaction of Sp1 with the 
OPG MolHaps was detectable. Sp1 represents a sequence specific protein, interacting 
specifically with GC-box promoter elements [Briggs et al, 1986]. In case of TATA-less 
promoters, activators, such as Sp1, are proposed to associate physically with TBP and 
thereby recruit the TFIID complex [Pugh and Tjian, 1991].  
Further, occurrence of the -960C allele of MolHap4 generates a putative binding site for 
NF-1, whose interaction was detectable with all three MolHaps in EMSA experiments in both 
cell lines, and could be confirmed with ChIP in U2Os cells. Sequence analysis led to the 
identification of NF1/A, NF1/B, NF1/C, NF1/L and NF1/X [Rupp et al, 1990; Kruse et al, 
1991]. This diversity is further increased by differential RNA splicing [Santoro et al, 1988]. In 
co-transfection analyses family members NF-1/A (repressing) and NF-1/B (activating) were 
identified as potential interaction partners. While the repressing effect of NF-1/A was nearly 
equal for all three MolHaps, the activating effect of NF-1/B was most pronounced for 
MolHap2, suggesting an increased affinity of NF-1/B for that haplotype constellation. As 
shown for other activating proteins, NF-1 family members can also mediate repression at 
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some promoters. The glutathione transferase P promoter contains a consensus NF-1 site 
that acts as a silencer and is bound by NF-1/A [Osada et al, 1997]. The mechanism by which 
NF-1 represses genes is not clearly understood, but results indicate that direct repression 
may work either through recruitment of co-repressors or interaction with the basal 
transcription machinery [Osada et al, 1997]. NF1/X, for example, was shown to specifically 
interact with Sp1 via its subtype-specific domain and block Sp1 induction of the PDGF A-
chain promoter [Rafty et al, 2002]. 
 
5.3.2. OPG T-159C 
In silico analyses predicted clustered binding sites of Egr1 and Sp1 at the T-159C 
polymorphic site. Indeed, Sp1 and Egr1 share very similar cognate binding sites; hence at 
many promoters, Sp1 sites overlap with binding sites for Egr1, but binding of Sp1 and Egr1 
is often mutually exclusive [Hsu et al, 2009]. Both TF compete, dependent of the 
physiological state of a cell, for binding at the cognate sites. For the platelet-derived growth 
factor A-chain promoter, containing overlapping Sp1 and Egr1 sites, Sp1 mediates basal 
transcription, while PMA-induced Egr1 displaces Sp1 and stimulates gene expression 
[Khachigian et al, 1995]. While Sp1 is an activating transcription factor, it has been shown 
that Egr1 can also act as a repressor, e.g. of a constitutively expressed collagen gene, by 
preventing interactions between Sp1 and the general transcriptional machinery [Tan et al, 
2003]. EMSA experiments revealed protein binding exclusively to the -159T allele and 
competition assays defined Egr1, not Sp1, as the protein binding to -159T allele. In ChIP 
assays, Egr1 as well as Sp1 were detected. Hence, it is quite conceivable that both proteins 
compete for binding at this cognate site, and bind context-specific with different affinities to 
the respective allele. Further, in both cell lines binding of NF-1 to this promoter portion was 
shown (ChIP). Since NF-1 was found to interact with the sequence spanning the MolHaps, 
an interaction of the MolHap-portion (NF-1) with the T-159C site (Egr1/Sp1) seems possible. 
Interaction of Sp1 and NF-1 has already been described [Rafty et al, 2002]. 
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Figure 36 Sp1 alters DNA structure. (A) Sp1 mediated DNA bending brings enhancer elements 
close to the basal promoter complex. (B) Mutation of Sp1 binding sites (indicated by the Xs) reduces 
DNA bending and transcriptional activation [Fry and Farnham, 1999]. 
 
Sp1 can also achieve context-dependent transcriptional activation by altering the structure of 
DNA. As shown for the T-159C spanning sequence, the SV40 early promoter is composed of 
clustered binding sites for Sp1, and robust transcriptional activity from this promoter also 
requires an upstream enhancer that binds a number of different transcription factors. The 
clustered repeats contain an intrinsic DNA bend that can be stabilized by binding of Sp1 
[Sun and Hurley, 1994]. It has been proposed that Sp1-stabilized bending activates 
transcription by bringing the factors bound to the upstream enhancer closer to the basal 
promoter (Figure 36). Courey et al demonstrated that Sp1 proteins bound 1.8 kb downstream 
of a promoter can cooperate with Sp1 bound at the basal promoter region to synergistically 
activate transcription [Courey et al, 1989]. 
Further hints of an interaction of the MolHap-site with the T-159C site were obtained by 
generating and analyzing serial deletion constructs (see below). 
 
5.4. Identification of a cis-active element by serial deletion 
constructs 
To define regions being involved in transcriptional activity of OPG, serial deletion constructs 
of the 5’-flanking region were generated and transiently transfected. Deletion construct 
analyses are also useful to mimic the impact of physical inactivation of DNA portions by 
nuclear histone packaging. The full length construct Del1 (-1020 to -13) displayed a sufficient 
transcriptional activity in both cell lines, while 5’-truncation of 84 bp (Del2 [-936 to -13]) 
resulted in a completely abrogated transcriptional activity, even below the level of the empty 
vector, strongly indicating a cis-active element within the truncated 84 bp (-1020/-936). The 
loss of transcriptional activity was also seen for the further truncated constructs (Del3 [-677 
to -13] and Del4 [-287 to -13]). Interestingly, and controversially to the full length constructs, 
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introduction of the -159C allele into the respective deletion constructs resulted in a highly 
significant increase of transcriptional activity, supporting the idea of a cis-active element 
within the 84 bp (bp -1020/-936) interacting with the T-159C site. The obtained results further 
indicate that this supposed interaction triggers Egr1 to activate or repress OPG transcription 
depending on the accessibility of the -1020/-936 promoter portion (e.g. in case of concealing 
by histone binding). 
Egr1 belongs to the family of zinc finger transcription factors, consisting of a DNA-binding 
domain (with 3 zinc finger motifs), an activation domain, and an inhibitory domain, located 
between the activation and the DNA-binding domain [Russo et al, 1995; Gashler et al, 1993]. 
Egr1 is a master regulator controlling the expression of a variety of genes, including 
transcription factors, signaling factors, growth factors, and cytokines [Fu et al, 2003]. Gene 
expression depending on Egr1 involves a functional cooperativity between Egr1 and a 
growing number of other regulatory factors, including among others the glucocorticoid 
receptor and AP-2 [Wong et al, 1998], RelA (p65) [Cogswell et al, 1997; Chapman and 
Perkins, 2002], p300 [Mouillet et al, 2004], and Sp1 [Srivastava et al, 1998]. Therefore, it 
seems likely that Egr1 does not act alone, but in concert with other transcription factors. 
Transcription factor modules, in which participation of Erg1 facilitates assembly and function 
of the complex, may either not form or be destabilized by the absence of Egr1 [Yan et al, 
2000]. 
The variants T-960C and A-946G are located within the truncated 84 bp, and in silico 
analyses predicted a NFκB binding site within (Figure 17). Interactions of Egr1 with members 
of the NFκB family have already been described. In many NFκB responsive promoters, 
NFκB-proteins alone are insufficient to activate transcription [Baldwin, 1996]. Egr1 and RelA 
(p65) cooperatively stimulate transcription of the NFκB1 (p50) gene [Cogswell et al, 1997], 
and Chapman and Perkins reported an interaction of RelA (p65), similar to its interaction with 
Sp1, with the zinc-finger domain of Egr1. But contrary to Sp1, Egr1 represses transcriptional 
activity of RelA, possibly by sequestering RelA from its target promoter [Chapman and 
Perkins, 2002]. Taken these results together, it seems to be likely that Egr1 is capable of 
interacting cooperatively with NFκB in some promoter contexts, while sequestering and 
inhibiting in others. 
The NFκB pathway is important for the expression of a variety of genes involved in immune 
and inflammatory response, cellular proliferation, and survival. The NFκB protein family 
members are ubiquitously expressed transcription factors: p65 (RelA), RelB, c-Rel, p50 
(NFκB1, precursor p105), and p52 (NFκB2, precursor p100) [Yamamoto and Gaynor, 2004]. 
Signaling is primarily regulated by inhibitor κB proteins (IκB) and the IκB kinase complex 
(IKK) through two main pathways. In the canonical pathway, NFκB dimers (e.g. p50/RelA) 
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are located in the cytoplasm, bound to an IκB protein. Binding of a ligand to a cell surface 
receptor (e.g. TNFα to its receptor TNFR) leads to the recruitment of adaptor proteins (e.g. 
TRAF or RIP), which in turn recruit the IKK complex (consisting of the α and β catalytic 
subunit and two regulatory units [NEMO]). The IKK then phosphorylates the IκB leading to 
proteasomal degradation, while the NFκB dimer enters the nucleus and binds to its target 
sequence. The non-canonical pathway is for the p100/RelB activation during B- and T-cell 
organ development. Receptor binding leads to the activation of the NFκB inducing kinase 
(NIK) which phosphorylates and activates the IKKα complex (containing two α subunits, but 
no NEMO). IKKα in turn phosphorylates two serine residues of p100 leading to its partial 
proteolysis and the release of the p52/RelB complex, entering the nucleus [Gilmore, 2006]. 
 
5.5. A model of transcriptional regulation of OPG 
Cis-active elements concert transcriptional activity by interaction with TFs that assemble at 
the promoter as modules rather than acting alone. The composition of an individual module 
and the composition of several modules is dependent on the genomic context and proteomic 
conditions, hence is cell type- and physiologically specific. Taking all results, as well as 
previous reports into account, the following model of transcriptional regulation of the OPG 
gene is conceivable: Based on the sufficiently active full length construct (1008 bp) harboring 
the wt sequence, transcription may be regulated by transcription factors Sp1, NF-1, NFκB, 
and Egr1 acting in concert and achieving sufficient transcriptional activity (Figure 37A). This 
interaction is possibly mediated by a Sp1 stabilized DNA bend [Fry and Farnham, 1999]. 
Introduction of the -159C allele (Figure 37B, black bar) leads to an altered TFBS to which 
Egr1 is not capable to bind and stimulate transcription in cooperation with Sp1, NF-1, and 
NFκB. This results in a decreased activity, indicating that Egr1 is adequate but not essential 
for transcriptional activity in the context of the full length. Altered transcriptional activities of 
the OPG MolHaps, seen in the full length construct, may be caused by an altered protein 
binding pattern of the TFs, as shown for Sp1 and NF-1. But occurrence of the haplotype 
constellations wt, MolHap2, and MolHap4 may not cause the loss of one TFBS, rather an 
attenuated binding affinity of a TF to its respective TFBS, resulting in a decreased 
transcriptional activity as observed. Indeed, binding affinity can be that attenuated, being 
below the detection limit of an EMSA. 
Truncation of the 1008 bp full length construct about 84 bp resulted in a completely 
abrogated transcriptional activity, caused, following this model, by the truncation of TFBS for 
Sp1, NF-1, and NFκB (Figure 37, red dashed box). Binding of Egr1 alone seems to repress 
transcriptional activity (Figure 37C, dotted arrow), because in case of the -159C allele and a 
not-binding of Egr1, transcriptional activity is partial restored (Figure 37D), possibly reflecting 
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the activity of the basal transcription machinery. Truncation of a full length construct is a 
good tool to mimic the impact of physical inactivation of DNA portions, e.g. by nuclear 
histone packaging. This indicates that the cis-active element (-1020/-936; TFBS for Sp1, 
NF-1, and NFκB), more precisely the accessibility of the cis-active element, is essential for a 
sufficient transcriptional activity. Moreover, both, the T-159C site and the MolHap spanning 
sequence, require one another to facilitate a sufficient transcriptional activity of the OPG 
gene promoter. As also seen in transient transfection analyses, with both polymorphic sites 
(MolHaps and T-159C) separated, transcriptional activities at the level of the shuttle vector 
were detected. Besides further evidence that transcription factors act as modules, within this 
model it is also shown that an altered composition of the module has differential 
consequences for transcriptional activity, and that factors in a module do have different 
weightings for the stimulation of transcription. 
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Figure 37 Proposed transcriptional regulation of OPG. (A) Sp1 (green), NF-1 (red), and NFκB 
(blue) bind to the distal promoter portion harboring the MolHap constellations (white box with black 
bars), and interact with Egr1 (violet), bound to the -159T allele (white bar), to cooperatively stimulate 
transcription (black arrow). (B) Introduction of the -159C allele leads to an attenuated binding-affinity of 
Egr1; as a consequence, the transcriptional module is altered in its composition and transcriptional 
activity is decreased (interrupted arrow). (C) Truncation (red dashed bar) leads to a loss of TFBS for 
Sp1 (green), NF-1 (red), and NFκB (blue), while Egr1 (violet) alone seems to act as a repressor 
(dotted arrow). (D) Additional introduction of the -159C allele (black bar) into to the truncated 
constructs results in a partial restoration of transcriptional activity. 
Certainly, the provided hypothesis for the transcriptional regulation of the OPG gene needs 
to be further confirmed in continuative experiments. Projects involving studying the 
protein:protein interactions and the precise composition, as well as additional TF of the 
suggested module are conceivable. Therefore, functional-identificatory methods (e.g. 
co-immunoprecipitations, Yeast-One-Hybrid) and biophysical approaches (mass 
spectrometry, multiple isotope labeling, multiple reaction monitoring) are useful. Further, it 
would be quite interesting to study the transcriptional regulation and the module composition 
under stimulatory conditions (e.g. TNFα, TGFβ, 17β-Estradiol). 
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5.6. Conclusion 
The clinical progression of arteriosclerosis and cardiovascular outcome is influenced by 
environmental and lifestyle factors, and strongly determined by individual genetic 
predispositions [Marenberg et al, 1994]. Identification of genetic variants with whole-genome 
approaches and consequently functional analyses may therefore help gaining a better 
understanding of the pathophysiology and aetiology of arteriosclerosis [Cambien and Tiret, 
2007]. DNA micro array technologies in genome-wide association studies enable genotyping 
of large study cohorts. Nevertheless, it is mandatory to profile the functional basis of the 
identified genetic variants [Brand-Herrmann, 2008]. Only 3% of the human genome are 
coding regions, while the remaining 97% represent introns, regulatory regions, and 
intergenic regions. These intergenic regions, former described as “junk DNA”, play an 
emerging role in understanding gene regulatory mechanisms. As a result of the HapMap 
project, genetic variants associated with a certain disease were detected within these 
regions, with no idea of their functionality. Thus, the role of intergenic regions is not yet 
clarified. One presumption is that they represent a bank of advantageous new genes, but 
they may also be evolutionary artefacts encoding for proteins that are no longer expressed 
(pseudo-genes). It becomes more and more evident that pseudo-genes may have gene 
regulatory properties. It is supposed that every 10th pseudo-gene is transcribed, and it was 
already shown that RNA of a pseudo-gene can silence transcription of its “regular” gene 
[Korneev et al, 1999]. Genetic variants located in regulatory regions of a gene do not affect 
the resulting protein directly, but may have profounding transcriptional consequences. Since 
not only single genetic variants but also alternative promoter usage and epigenetic events 
can be associated with a certain disease, the entire structure of candidate gene promoters 
needs to be investigated.  
Single genetic variants within regulatory regions may cause alterations in the function of 
TFBS. But, as mentioned before, a physical TFBS requires the cellular and genomic context 
to be functional. For that reason, analyses of naturally occurring, molecular haplotype 
constellations are reasonable. As shown in this study, single genetic variants (T-159C) and 
haplotype constellations do have sufficient cell type-specific effects on transcriptional 
regulation of the analyzed OPG gene. These effects were more or less pronounced 
depending on the accessibility of a newly identified cis-active region, which in turn may 
depend on histone modifications, e.g. acetylation of lysine. Alterations of TFBS may cause 
altered binding affinities of a respective TF (e.g. Egr1 for the -159C allele). As a 
consequence, an increased stoichiometric availability of the TF is needed to sustain the 
biologic function. This in turn depends, amongst other factors, on the individual genetic 
background of the respective transcription factor.  
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Environmental factors may influence the epigenetic signature of an individual, and 
depending on its genetic background, the analyzed variants in the OPG promoter region may 
have different consequences for OPG expression and thus for the individual risk of vascular 
calcification and arteriosclerosis. As OPG is assumed to have protective role in CVD and 
vascular calcification, patients carrying MolHap2 and MolHap4, as well as the -159C allele, 
may have an additional risk factor for the incidence of vascular calcification and/or 
arteriosclerosis. 
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6. Outlook 
The genetic predisposition for complex diseases such as CAD is undisputed, but escapes 
comprehensive explanation of its development, progression, and severity. With the help of 
genome-wide association studies and candidate gene approaches, single-genetic variants 
were identified with a highly significant association with progression and severity of CAD. 
Since the molecular functionality of these variants in their genomic context is not understood 
yet, findings are not sufficiently valuable for risk stratification. Therefore, it is mandatory to 
understand the modularly functionality of human gene promoters. Currently, a change of 
concept of the understanding of how the human genome works emerges. Erstwhile, the 
nature of the human genome was considered to be a collection of individual programs 
(genes), while the modern concept is rather that of an interconnected, dynamic 
data-processing system software with the capability to interact and “learn” by e.g. epigenetic 
events. Modern promoter concepts also consider flexible adjustments to change 
circumstances, comprising transcriptional modules, selection and utilization of alternative 
promoters, and epigenetics. 
Functional SNPs, like those OPG haplotypes identified and characterized in this study, may 
serve as a valuable tool for differentiation- and cell type-specific gene activation, and for 
analyzing the impact of cis-regulatory elements, acting in concert in the natural context of the 
human genome; molecular haplotypes may be realized as “in situ deletions”. The 
understanding of the stated function of individual haplotypes offer for a better risk 
stratification than any individual SNP. Advantageous concepts support the idea of an 
individual genome. 
New approaches no longer focus on single candidate genes or one genetic predisposition. 
Based on large-scale gene expression data and linkage analyses, altered transcriptional 
modules and deflected pathways with a potential role in the pathophysiology of 
arteriosclerosis, or other complex disease, are identified and functionally analyzed. 
Therefore, it should further be analyzed whether the TF module, identified within this work 
and supposedly involved in OPG gene regulation, is involved in pro-inflammatory or 
inflammation-response pathways. Highly associated genetic variants identified in linkage 
analyses may fail to display any effects in functional analyses. Meanwhile, it is assumed that 
these variants may play an important role during differentiation processes, and thus are 
“silent” in differentiated tissues. In future, body’s own cells might be de-differentiated into 
pluri-potent stem cells, and subsequently re-differentiated into cardiomyocytes. 
Understanding of the complexity of the individuality of each single human genome, based on 
the individuality of the composing haplotypes has just begun. 
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8. Appendix 
8.1. SNPs identified in the OPG gene 
 
Table 1. SNPs identified in the OPG gene with their according rs number and region of 
appearance. 
SNP region
T-960C rs3134071 5´-flanking region
A-946G rs3102735 5´-flanking region
G-900A rs3134070 5´-flanking region
T-864G rs3134069 5´-flanking region
T-159C rs2073617 5´-flanking region
G+73C rs2073618 exon 1
C1217T rs3102734 intron 1
Ins/Del/ct 6533/34 rs10554146 intron 3
A+832G rs7844577 exon 4 
A8731C rs7844539 intron 4
 
 
 
8.2. Oligonucleotide sequences by application 
 
Table 2. Nucleotide sequences for diagnostic PCR. In general overlapping exon-intron-boundaries. 
Name Sequence  5'-3' Position Accession #/ Ref
OPGdiag SS CTC GTG TTT CTG GAC ATC bp 119 U94332
OPGdiag AS ACA GGG TAA CAT CTA TTC C bp 698 U94332
OPG TSS1 SS GGA GAC GCA CCG GAG C bp 1110 AB008822
OPG TSS2 SS CTG GAG CTT TCT GCA CA bp 952 AB008822
OPG TSS3 SS ACT CCC CGA AAA GGG CTC AGA bp 922 AB008822
OPG TSS4 SS ACT CCC CGA AAA GGG CTC AGA bp 506 AB008822
hRP27 SS CCA GGA TAA GGA AGG AAT TCC TCC TG bp 128 NM_002954.3
hRP27 AS CCA GCA CCA CAT TCA TCA GAA GG bp 424 NM_002954.3
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Table 3. Nucleotide sequences for cloning. 5’ added nucleotides for creating restriction sites for 
endonucleases are bold. 
Name Sequence  5'-3' Position Accession #/ Ref
OPG MolHap SS-SacI AGA GCT CA ACC CGC GAA CTG TAA TCC ATG bp 88 AB008822
OPG MolHap AS-NheI AGC TAG CA TAA CCT TGC GGA GCA CTG bp337 AB008822
OPG-159 SS AGC CGC CTT GTT CCT CAG bp 822 AB008822
OPG-159 AS GAG AGA TCT  CTC ATC ACG TTA TAT ATA GCG TCC bp 1096 AB008822
OPG-Del1 SS-SacI AGA GCT CA ACC CGC GAA CTG TAA TCC ATG bp 88 AB008822
OPG-Del2 SS-SacI AGA GCT CAC AGC GAA CCC TAG AGC bp 173 AB008822
OPG-Del3 SS-SacI AGA GCT CTA GGG CCA ATC AGA CAT TAG TTA G bp 428 AB008822
OPG-Del4 SS-SacI AGA GCT CAG CCG CCT TGT TCC TCA G bp 822 AB008822
OPG Del AS-BglIII GAG AGA TCT CTC ATC ACG TTA TAT ATA GCG TCC bp 1096 AB008822
 
 
 
Table 4. Nucleotide sequences for EMSA sequencing reaction. 
Name Sequence  5'-3' Position Accession #/ Ref
OPG Seq SS TAG GGC CAA TCA GAC ATT AGT TAG bp 432 AB008822
OPG Seq AS TTC ACT TCG GGT TCT GAA ACC TC bp 582 AB008822
pGL3 SS AGT GCA AGT GCA GGT GCC AG bp 90 U47295
pGL3 AS CTT TAT GTT TTT GGC GTC TTC C bp4781 U47295
 
 
 
Table 5. Nucleotide sequences for site-directed mutagenesis.  
Name Sequence  5'-3' Position Accession #/ Ref
OPG mut-957 GTC ATC AAG TCT AAC TTC CAG ACC AGG GAA TTG ATG G bp 131 AB008822
OPG mut-897 GCA AAG TGC CAA ACT TCT GTC AAT AGC TTG bp 188 AB008822
OPG mut-861 GGA AAG ACC TCG AGG AGG CGA CTC CAG AAG TT bp 226 AB008822
 
 
 
Table 6. Nucleotide sequences for RACE. 
Name Sequence  5'-3' Position Accession #/ Ref
RACE cDNA snth. CGC TCT GGG GTT CCA GCT T bp 507 U94332
RACE anchor GAC CAC GCG TAT CGA TGT CGA C(T)16 Kit #3353621001
RACE adaptor SS GAC CAC GCG TAT CGA TGT CGA C Kit #3353621001
RACE PCR AS CCT GGG TGG TCC ACT TAA TGG A bp 158 U94332
RACE Seq CGA GCG CGC AGC ACA GCA A bp 122 U94332
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Table 7. Nucleotide sequences for sequencing reaction. 
Name Sequence  5'-3' Position Accession #/ Ref
OPG Seq SS TAG GGC CAA TCA GAC ATT AGT TAG bp 432 AB008822
OPG Seq AS TTC ACT TCG GGT TCT GAA ACC TC bp 582 AB008822
pGL3 SS AGT GCA AGT GCA GGT GCC AG bp 90 U47295
pGL3 AS CTT TAT GTT TTT GGC GTC TTC C bp4781 U47295
 
 
 
Table 8. Nucleotide sequences for EMSA probes. 
Name Sequence  5'-3' Position Accession #/ Ref
EMSA Oligo -156 SS CCC TGA AAG CGT TAA T/C CCT GGA GCT TTC TGC bp 935 AB008822
EMSA Oligo -156 AS GCA GAA AGC TCC AGG A/G TTA ACG CTT TCA GGG bp 965 AB008822
Egr-1 consensus CCT CCC CCC GCC TTG CCC GGG GTT GTG G Koyano-Nakagawa et al, 1994 
NF-1 consensus GGG CTA GAT GGC TGC CAG CCA AGG CTT CAT
Sp1 consensus ATT CGA TCG GGG CGG GGC GAG C
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